Stockwinners Market Radar for August 03, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:28 EDT SPDR Gold Shares holdings rise to 1,248.38MT to 1,241.95MT - This is the highest level of holdings since March of 2013.

18:48 EDT S&P Global director sells 5.9K shares of common stock - In a regulatory filing, S&P Global disclosed that the president of S&P Ratings, John Berisford, sold 5,940 shares of common stock on July 30th in a transaction size of $2.1M.

18:34 EDT Clorox CEO: We have so much momentum with our business - In an interview on CNBC's Mad Money, Benno Dorer said the company is seeing broad-based strength across its units. Market share and household penetration are both growing. "We're seeing improved fundamentals," Dorer said. "This is a time when consumers are in need of brands they trust, and we have plenty of them," he noted. The company's core focus will be the U.S., but it's also looking at International opportunities for growth.

17:58 EDT Twitter faces FTC fine of up to $250M over alleged misuse of email, phone data - On July 28, 2020, Twitter received a draft complaint from the Federal Trade Commission alleging violations of the company's 2011 consent order with the FTC and the FTC Act, the company said in a regulatory filing. The allegations relate to the company's use of phone number and/or email address data provided for safety and security purposes for targeted advertising during periods between 2013 and 2019. The company estimates that the range of probable loss in this matter is $150M to $250M and has recorded an accrual of $150M. The accrual is included in accrued and other current liabilities in the consolidated balance sheet and in general and administrative expenses in the consolidated statements of operations. The matter remains unresolved, and there can be no assurance as to the timing or the terms of any final outcome. The company is also currently involved in, and may in the future be involved in, legal proceedings, claims, investigations, and government inquiries and investigations arising in the ordinary course of business. These proceedings, which include both individual and class action litigation and administrative proceedings, have included, but are not limited to matters involving content on the platform, intellectual property, privacy, data protection, securities, employment and contractual rights. Legal fees and other costs associated with such actions are expensed as incurred. The company assesses, in conjunction with its legal counsel, the need to record a liability for litigation and contingencies. Litigation accruals are recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. Material loss contingencies that are reasonably possible of occurrence, if any, are subject to disclosure. As of June 30, 2020, except for the referenced class actions, derivative actions and FTC matter, there was no litigation or contingency with at least a reasonable possibility of a material loss. Except for the aforementioned accrual of $150M recorded in relation to the FTC matter, no other material losses were recorded during the three and six months ended June 30, 2020 and 2019 with respect to litigation or loss contingencies.

17:23 EDT Cubic subsidiary awarded $172M maximum USSOCOM procurement contract - GATR Technologies, a subsidiary of Cubic, was awarded a $172M maximum ceiling, single-award, indefinite-delivery/indefinite-quality, firm-fixed-price contract with five one-year ordering periods for the procurement of 1.2 meter and 2.4 meter ground antenna transmit and receive, or GATR, inflatable satellite communications terminals and ancillary equipment in support of U.S. Special Operations Command, or USSOCOM. FY20 procurements funds in the amount of $5,000 are being obligated at the time of award. The contract will be funded with operations and maintenance funds, as well as procurement funds, from multiple fiscal years over the life of the contract. The majority of the work will be performed in Huntsville and is expected to be completed by August 2025. The contract is a Phase III Small Business Innovation Research award authorized under Title 10, U.S. Code 2304 or Title 41, U.S. Code 253. USSOCOM is the contracting activity.

17:06 EDT Range Resources sees FY20 production of 2.25 Bcfe per day - Sees FY20 Appalachia production of 2.15 Bcfe per day.

17:06 EDT American Water subsidiary acquires Royal Pines Village water system - Iowa American Water, a subsidiary of American Water, announced the company's acquisition of the water system of the Royal Pines Village Mobile Home Park in Clinton. The acquisition of the water system adds 131 new customers to the company's customer base.

17:05 EDT EnPro to sell its STEMCO Air Springs unit to Turnspire affiliate - EnPro Industries announced that it has entered into a definitive agreement to sell its STEMCO Air Springs business unit, manufacturer of Goodyear-licensed air springs, as well as Super Cushion and Spring Ride air springs, to an affiliate of private equity firm Turnspire Capital Partners. The agreement provides for the sale of the Air Springs business for $32M in cash and a long-term promissory note with a face value of $7.5M that will be stated at fair value. The purchase price is subject to adjustment based on the amount of cash and working capital on the closing date. "The sale of STEMCO's Air Springs business marks a significant milestone in our portfolio reshaping effort within STEMCO and significantly reduces EnPro's exposure to the commercial vehicle and heavy-duty truck markets. Over the past year, we have conducted an extensive review of our portfolio of companies to identify businesses and product lines that are no longer aligned with our long-term objectives. Based on this work, we have exited several product lines and divested several businesses to reduce our heavy-duty truck exposure. We are pleased to share that we expect to complete this transaction as well as the other announced exits in line with the year-end 2020 timeline that we previously communicated," said Marvin Riley, President and Chief Executive Officer.

17:03 EDT Valvoline sees FY20 adjusted EBITDA $475M-$485M - "The resiliency of our business model drove a strong recovery across our segments during Q3, as miles driven trends improved from the unprecedented declines caused by early-stage COVID-19 restrictions," said CEO Sam Mitchell. "Looking forward to Q4, the quarter is off to a good start based on our early view of July results, including same-store sales growth that is expected to come in ahead of June levels. Barring any unexpected impacts from COVID-19, for Q4 we anticipate same-stores sales growth to be in the high-single digits, leading to our 14th straight year of growth. While uncertainty related to COVID-19 remains, given current trends we expect our FY20 adjusted EBITDA to be in the range of $475 million to $485 million, in line with last year. Reaching these expectations would be an impressive achievement given the significant negative impact that COVID-19 has had on our results this year."

16:59 EDT Atlas Technical Consultants announces agreement to acquire Alta Vista - Atlas Technical Consultants announced that it has entered into a definitive agreement to acquire Alta Vista Solutions, headquartered in Oakland, California. Alta Vista has approximately 100 employees, operating out of four offices in California and one office in New York City, bringing a broad array of construction engineering, materials testing, inspection, quality management, asset management and infrastructure services. L. Joe Boyer, Atlas' Chief Executive Officer, said, "Alta Vista's transportation focus, wide range of services and established presence in California and New York will provide an exceptional fit for Atlas. The ability to self-perform more work is a key part of our growth strategy. With our combined expertise and infrastructure focus, we will be able to more thoroughly service customers in two key regions where investment in transportation is an increasing priority for state and local governments. We look forward to welcome Alta Vista's talented team to our rapidly growing company." The transaction is expected to close in the third quarter of 2020. The terms of the acquisition were not disclosed.

16:57 EDT Exagen announces APS collaboration with Hospital for Special Surgery - Exagen announced a collaboration with Hospital for Special Surgery, or HSS, in New York City. This institution is an academic medical center for autoimmune diseases and musculoskeletal health. Antiphospholipid syndrome, or APS, is an autoimmune clotting disorder which most commonly increases the risk of blood clots and pregnancy complications as a result of antiphospholipid antibodies, or aPL. Complement cascade, which is part of the immune system, is involved in the development of aPL-related clinical problems. This proof-of-concept clinical study, led by Doruk Erkan, rheumatologist at the Barbara Volcker Center for Women and Rheumatic Diseases at HSS, will investigate complement activation markers, and additional biomarkers, in different subgroups of aPL-positive patients.

16:55 EDT eXp World Holdings acquires Showcase IDX - eXp World Holdings announced it has acquired all the assets of Showcase IDX, a real estate search technology company that helps agents market and grow their businesses and online presence. Showcase IDX's services include property search for online and mobile platforms, lead generation, mapping and CRM tools and integrations. With this acquisition, eXp will be able to focus on creating a consumer portal and innovation in the home-search technology space. Showcase IDX will continue the growth of its existing IDX product and business. Founded in 2003, Showcase IDX's customers include thousands of agents from the United States' brokerages. Showcase IDX will be wholly owned by eXp World Holdings, but its business will remain separate and continue to operate its services for customers. Showcase IDX's Founder and CEO Scott Lockhart and all staff will remain, moving the company's Atlanta-based operations to a team suite in VirBELA Open Campus.

16:49 EDT Virgin Galactic down 6% after announcing stock offering

16:44 EDT Mosaic says underlying fundamentals for strong second half of 2020 in place - The company sates: "The underlying fundamentals for a strong second half of 2020 are in place. Generally, growers around the world are experiencing good returns for their crops, affordable inputs and favorable weather. Fertilizer inventories around the world have been drawn down over the first half of 2020 and key fertilizer markets such as India and Brazil are experiencing strong year over year growth heading into their peak application seasons. In fact, potash and phosphate shipments in both India and Brazil are on pace to beat their 2019 shipments. In North America, recovery of the ethanol market and potentially higher corn exports to China are driving an improved outlook, particularly for the 2021 crop prices that will influence this fall's fertilizer decisions. Tightness in China's corn market also appears to be driving domestic demand and consumption of all fertilizers, with the potential to post their first year-over-year increases in several years. Palm oil prices have staged a sharp recovery, somethingwhich typically portends a rebound in potash demand in Southeast Asia.Prices for phosphate fertilizer products have strengthened globally, reflecting tightening of the supply and demand balance. Potash prices are expected to be stable, after an increase of most global benchmarks following the settlement of the China and India contracts. The risks posed by Covid-19 are expected to persist through at least the rest of the year, however agriculture and agricultural inputs continue to be prioritized globallyto ensure food supply for the world's population."

16:43 EDT Mosaic reports quarterly record potash sales volume in Q2 of 2.6M tons - The company states: "Sales volumes in all three businesses in both the first and second quarters of 2020 were higher than the same periods one year ago. Agricultural growing conditions in North America are significantly improved year-over-year. Potash sales volume of 2.6 million tonnes was a quarterly record. Mosaic Fertilizantes recorded its best ever second quarter sales volume."

16:40 EDT Hyatt says existing liquidity can fund operations for next 36 months - Hyatt said, "The Company ended the second quarter of 2020 with a strong balance sheet, following numerous actions to secure additional access to liquidity and maintain financial flexibility. These actions provide the Company with adequate existing liquidity to fund operations for at least the next 36 months at second quarter 2020 demand levels."

16:38 EDT Hyatt says recovery in RevPAR has been mixed - Hyatt said, "The recovery in RevPAR has been mixed, as various parts of the world remain subject to travel restrictions and quarantines which continue to suppress demand and drive uncertainty surrounding the pace and timing of recovery across individual markets. Comparable system-wide RevPAR improved sequentially in each month after the low point in April. Greater China, where the impacts of the COVID-19 pandemic were first reported, continues to lead the recovery. RevPAR in Greater China has shown continued improvement since May, with preliminary estimates indicating occupancy reaching approximately 57% at the end of July. Excluding Hong Kong, Macau, and Taiwan, preliminary estimates indicate occupancy in China reached approximately 65% at the end of July. The recovery in Greater China and certain markets within the Americas and EAME/SW Asia regions is being led by strength in leisure transient demand."

16:38 EDT Investors Real Estate is not providing FY20 financial guidance - The company said, "On March 27, 2020 we issued a press release indicating that in light of the impact of COVID-19 on our business and results of operations, we were withdrawing our 2020 Financial Outlook. Given the ongoing impact of COVID-19, we are not providing an updated 2020 Financial Outlook at this time."

16:33 EDT NexTier Oilfield sees FY20 CapEx $100M-$120M - Capital expenditures in 2020 will be driven by strategic innovation investments and maintenance capital expenditures. Capital expenditures during the first half of 2020 were primarily driven by the delivery of certain strategic innovation investments, with second half of 2020 spending expected to be mainly driven by maintenance.

16:26 EDT Coherent names David Gee as Chief Marketing Officer - Coherent's President and CEO, Andy Mattes, announced significant updates to the company's senior leadership team. Mark Sobey EVP & COO, now oversees both the ILS and OLS business units under his leadership to increase operational best practices sharing and create efficiencies. In addition Coherent announced the appointment of its first Chief Marketing Officer. David Gee joins Coherent as SVP and CMO to help drive and support the company's sales and go-to-market strategy and accelerate its digital transformation. David brings more than two decades of sales and marketing leadership experience in international technology companies. Most recently, he served as CMO at Imperva, a leading cyber security company and previously, as CMO of Zuora, Infoblox, and held senior marketing positions at Hewlett-Packard, Yahoo!, Sun Microsystems, and IBM.

16:24 EDT Invitation Homes resumed placing acquisitions under contract in June - Invitation Homes CEO Dallas Tanner said: "This result would not have been possible without the differentiated locations of our homes, the scale of our portfolio in each market, and our local approach to asset management and resident service that enhances control over the resident experience. We believe these differentiators also position us optimally to capitalize on long-term growth fundamentals. We see a significant pipeline of demand in the millennial generation moving toward single-family rental over the next decade, and the ripple-effects of COVID-19 may further intensify preferences for single-family space over denser housing options. On top of organic growth, we see a compelling opportunity for long-term external growth, and we resumed placing acquisitions under contract in June."

16:19 EDT Bed Bath & Beyond completes sale of PersonalizationMall.com for $245M - Bed Bath & Beyond announced the completion of the sale of PersonalizationMall.com to 1-800-FLOWERS.COM for $245M, subject to certain customary post-closing adjustments. PMall will continue to provide product and personalization services to the Company's Bed Bath & Beyond and buybuy BABY retail concepts. The cash proceeds from this transaction further strengthen the Company's liquidity and financial flexibility as it continues to build a balanced, durable financial model. With respect to capital allocation strategies, in March 2020 the company postponed its plans for share repurchase and suspended dividends and planned debt reductions in light of the COVID-19 pandemic. Bed Bath & Beyond is committed to a balanced capital return program over the mid-to-long term and will re-evaluate when appropriate. The company continues to review its non-core assets for opportunities to further simplify its portfolio. In connection with the previously executed settlement agreement, the parties' counsel have executed a Stipulation and Proposed Order of Dismissal, which is expected to be filed one business day after closing and will result in the voluntary dismissal with prejudice of the litigation relating to the transaction.

16:17 EDT Durect started recruiting Phase 2 DUR-928 study in COVID patients - The company said, "We have begun to recruit patients for a randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 infected patients with acute liver or kidney injury. A total of approximately 80 patients are planned to be enrolled into two study treatment groups in a 3:1 (DUR-928: placebo) ratio. Patients will receive a dose of 150 mg of DUR-928 or placebo by intravenous infusion on day 1 and day 4 in combination with standard of care therapy, which will be determined by the principal investigator (PI) at each clinical trial site. The primary efficacy endpoint is a composite of survival and being free of acute organ failure (free of mechanical ventilation, free of liver failure events and free of renal replacement therapy) at day 28. Patients will be followed for 60 days. Should any drug product be determined by the FDA to be safe and effective for the treatment of COVID-19 while the trial is ongoing, such treatments may be offered, at each PI's discretion, to any remaining and future patients in this trial."

16:15 EDT Medallion Financial CFO says lowering medallion collateral value to $119.5K - Larry Hall, Medallion's CFO, stated, "It is apparent that COVID-19 continues to have a significant impact on the NYC economy and the taxi industry. New York City medallion transfer activity in June resulted in the Company lowering its collateral value from $124,500 net to $119,500 net. The Company's net medallion loan portfolio, exclusive of loan collateral in the process of foreclosure, was $84 million at the end of the second quarter, a $12 million reduction from the first quarter. All loans 90 days or more past due have been written down to collateral value, while all current medallion loans have a 21% general reserve. This quarter we saw approximately $1.5 million in recoveries on the medallion portfolio. Though this remains a focus for us, the recovery process is difficult to predict, particularly in these uncertain times, and will likely remain choppy in the quarters ahead. Lastly, operating expenses decreased $3.1 million from the first quarter as we reduced expenses."

16:13 EDT Texas Roadhouse says July period SSS decreased 13.0% - For the July period, comparable restaurant sales at company restaurants decreased 13.0% and average weekly sales at all restaurants were $86,062. The decrease in average weekly sales was impacted by the decision of some states to further limit capacity or require dining rooms to be re-closed, the negative impact of the shift in the Fourth of July holiday, and normal seasonality. As of the end of July, over 95% of company restaurants had dining rooms operating in a limited capacity. For the July period, comparable restaurant sales per week and the average weekly sales for all company restaurants were as follows:

16:12 EDT Itron sees FY20 free cash flow to be positive - Itron said: "We currently have all factories up and running with aggressive measures to drive safety across our entire operation. Our supply chain and logistics situation has stabilized. And while there have been intermittent shortages, none has been at sustained levels. We continue investments necessary for our long-term strategy and will continue to position ourselves to capture the growing need for technology and outcomes in our industry. Our teams have begun to re-enter some customer sites and help our customers plan for and in some cases resume deployments. To date there have been no order cancellations or issues with collections from our customers. We are observing that utilities and municipalities are recovering at varying rates across the globe. Our customers' priority is supplying essential services to their communities and recovering from the impact of COVID-19. We see this impacting our business with reduced near-term demand and the delay of planned 2020 deployments into future quarters. We are aggressively managing our response in these unprecedented times by working closely with our customers to ensure alignment on their shipments, deployment schedules and ongoing operational activities. We will continue to keep tight controls on operating and capital expenditures and drive actions focused on improving margins as we continue our path toward our targeted 'asset light' operating model. Our services remain essential to our customers and the need for our solutions will increase as they begin to get back to normal operations. Due to the uncertainty of the impact of the COVID-19 pandemic, we suspended our full year 2020 guidance on May 4, 2020. With this unique situation, we will provide some insight into the second half of 2020 based on the best information we have today. Our current view of the second half of 2020 is consistent with comments made on our last earnings call. While we are seeing operating improvements in the second half of the year; we anticipate revenue and non-GAAP earnings per share to be on par with the first half of 2020, with neither quarter being larger than our first quarter performance. This also considers a higher non-GAAP, full year, effective tax rate of approximately 36% driven by an expected shift in the mix of income by jurisdiction. We anticipate the full year 2020 free cash flow to be positive, although at approximately half of our prior year's performance."

16:10 EDT Virgin Galactic sees Branson's flight occurring in 1Q21 - Along with its second quarter 2020 financial results, Virgin Galactic also provided an update regarding the ongoing impact of COVID-19 on its business and operations. The Company has implemented rigorous health and safety procedures and testing protocols for its employees, following guidelines from the CDC and state and local officials. The protocols and procedures implemented by the Company in response to the pandemic have limited the number of employees who are able to work on-site in the Company's facility in Mojave, California, and at Spaceport America, New Mexico, which has slowed the Company's pace. Virgin Galactic expects to advance to the next phase of its test flight program with its first powered spaceflight from Spaceport America this fall, with two test pilots in the cockpit. Virgin Galactic then expects to conduct a second powered space flight from Spaceport America, with a crew of two test pilots in the cockpit and four mission specialists in the cabin. Assuming both flights demonstrate the expected results, Virgin Galactic anticipates Sir Richard Branson's flight to occur in the first quarter of 2021. As always, safety remains the central focus, and the test flight program will progress with a step-by-step, diligent approach. Expected dates may adjust as the Company processes data from each of its test flights.

16:06 EDT Voyager provides update on AbbVie vectorized antibody collaborations - Voyager Therapeutics (VYGR) announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie (ABBV). Voyager retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations. "Our efforts to harness AAV-based gene therapy to produce antibodies directly in the brain and overcome major limitations with delivery of current biologics across the blood-brain barrier have been highly productive," said Omar Khwaja, M.D., Ph.D., Chief Medical Officer and Head of R&D at Voyager. "Through the tau and alpha-synuclein collaborations, we believe we have made considerable progress against targets for neurodegenerative diseases with this novel approach, reinforcing our enthusiasm for its potential to deliver therapeutically efficacious levels of biologics to the brain and central nervous system. We believe our continued work on discovery and design of novel AAV capsids with substantially improved blood-brain barrier penetrance will also considerably broaden the potential of AAV-based gene therapy, including vectorized antibodies or other biologics, for the treatment of severe neurological diseases." The tau and alpha-synuclein research collaborations were formed in 2018 and 2019, respectively. Under the terms of the collaboration agreements, Voyager received upfront payments to perform research and preclinical development of vectorized antibodies directed against tau and alpha-synuclein. With the conclusion of the collaborations, Voyager has regained full clinical development and commercialization rights to certain product candidates developed within the context of the collaboration for the tau program. Voyager is free to pursue vectorized antibody programs for tau and alpha-synuclein alone or in collaboration with another partner. Voyager does not anticipate any changes to its cash runway guidance due to the termination of the agreements. As of March 31, 2020, the Company had cash, cash equivalents and marketable debt securities of $250.9 million, which, along with amounts expected to be received for reimbursement of development costs from Neurocrine Biosciences, is expected to be sufficient to meet Voyager's projected operating expenses and capital expenditure requirements into mid-2022.

16:06 EDT Trex Company sees Q3 revenue $215M-$225M, consensus $193.94M - The company states: "For the third quarter of 2020, we expect consolidated net sales of approximately $215 million to $225 million, representing 13% year-over-year growth at the midpoint. With improved clarity in the market, we are again able to provide full year financial guidance. We expect full year 2020 incremental gross margin to be 45% to 50% inclusive of additional COVID-19 related expenses, full year SG&A as a percentage of sales to improve by 80 to 100 basis points compared to the prior year, a full year tax rate of approximately 25% and full year capital spending of $150 million to $170 million."

16:03 EDT Kennametal sees FY21 CapEx $110M-$130M - With the majority of the spending occurring in the first half of the fiscal year.

15:18 EDT 3M, Cinotop Electronics report patent license pact for 3M metal mesh technology - 3M, 3M Innovative Properties Co. and Cinotop Electronics Co., Ltd. have reached a patent license agreement for use of 3M's metal mesh technology, the companies announced. As part of the agreement, Cinotop has taken a royalty-bearing patent license from 3M. "Cinotop, as a quickly growing company, values intellectual property and we are proud to be the first Chinese metal mesh manufacturer to obtain a license from 3M. The 3M license provides Cinotop and our customers with the confidence to fuel our continued expansion," said Su Wei, chairman of Cinotop Electronics.

14:34 EDT FAA announces NPRM for Boeing 737 MAX airworthiness directive

14:05 EDT Geo Group awarded multi-Texas contract for detention facilities - The Department of Homeland Security, Immigration and Customs Enforcement, has awarded the GEO Group an IDIQ contract to provide detention and detention related services for Requirement A under Solicitation number 70CDCR20R0000001, according to a post to the SAM.gov website. The award date was July 30, 2020, with an effective date of August 6, 2020, the post stated. The total contract value, including base and all options, is listed as $564,052,290.60. Reference Link

13:16 EDT Ocean Bio-Chemical expands production of disinfectant Performacide - Ocean Bio-Chem announced that its subsidiary, Kinpak has commissioned a third production line for the manufacturing of its disinfectant/sanitizer product group Performacide. Performacide is an EPA-registered disinfectant that kills the SARS-CoV-2 virus, the cause of COVID-19, on hard surfaces.

12:17 EDT United Natural Foods announces long-term labor agreement in Fort Wayne - United Natural Foods issued the following statement regarding the long-term labor agreement that it has reached with Teamsters Local 414 in Fort Wayne, Indiana. Jill Sutton, UNFI's Chief Legal Officer, General Counsel and Corporate Secretary, commented: "We're very pleased that Teamsters Local 414 has ratified a new long-term labor agreement for our distribution center in Fort Wayne, Indiana. UNFI's four-year contract with Local 414 maintains competitive benefit and wage terms in line with other facilities in the Midwest. The contract also includes language updates that afford UNFI the flexibility it needs to operate and succeed as a competitive distribution business in today's landscape. We believe this resolution is a positive development for UNFI, our valued associates in Fort Wayne and our customers."

12:01 EDT Lincoln Educational announces re-opening of Queens, NY campus - Lincoln Educational Services announced that it has re-opened its Queens, NY campus and has resumed on-site instruction on a limited basis. "With the re-opening, all 22 Lincoln Tech campuses nationwide have now returned to at least some level of normal on-campus operations," the company stated.

12:00 EDT Resideo falls -19.7% - Resideo is down -19.7%, or -$2.62 to $10.66.

12:00 EDT Jernigan Capital rises 23.0% - Jernigan Capital is up 23.0%, or $3.23 to $17.23.

12:00 EDT ADT Inc. rises 58.5% - ADT Inc. is up 58.5%, or $5.04 to $13.65.

11:42 EDT ECMOHO enters $30M investment agreement with Anze - ECMOHO announced that it has entered into an investment agreement with Anze Premium Health and Beauty, a company involved in the research and development of Chinese herbal medicine-based health and wellness products. The Company has committed to paying Anze up to $30M, comprising of up to $15M for an equity interest in Anze and up to $15M for zero coupon convertible notes issued by Anze. The consideration to be paid by the Company will be payable over three installments, each payment being contingent upon the satisfaction of certain performance conditions by Anze, as set out in the transaction documents. Upon the completion of the third and final equity installment, the Company is expected to cumulatively own 29.7% of Anze's equity capital. The convertible notes shall be repaid in installments starting in the 1st quarter of 2021 and ending in 2023. The Company has the right to convert the convertible notes into equity at predetermined valuations starting in 2021. If the Company exercises its conversion right, the notes can be maximally converted into a 20% interest in the equity capital of Anze, as set out in the transaction documents.

11:00 EDT Toyota issues statement on reported COVID-19 infections at work sites - Toyota issued the following statement on reported COVID-19 infections at Toyota work sites: "We sincerely apologize for the anxiety and concern that this news may cause to people in the surrounding regions. The virus is an issue that has the potential to affect all Toyota locations and we are continuously working to further enhance our communication and health checks with staff at all locations. Toyota is actively implementing measures to prevent the further spread of the virus and remain committed to provide timely updates as the situation requires." The company also provided details on its website regarding the worksites impacted and the anticipated affects to production operations. Reference Link

10:13 EDT Loews: Share repurchases not off the table, but won't buy at same pace

10:06 EDT Loews CEO: This year will be 'wash-out' for entire hotel and travel industry

10:05 EDT AIkido Pharma regains compliance with Nasdaq listing requirements - AIkido Pharma announced that on July 31, 2020, the company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The company regained compliance with the NASDAQ's requirements when the closing bid price for the company's common stock was at or above $1.00 for ten consecutive business days.

10:02 EDT BetMGM signs with PGA Tour as official betting operator - The PGA TOUR announced that BetMGM has signed a multi-year content and marketing relationship to become an Official Betting Operator of the PGA TOUR. By joining the TOUR's Official Betting Operator program, BetMGM will have rights in the United States to use PGA TOUR marks, rights to advertise within TOUR media and TOUR partner platforms, plus content and video rights allowing BetMGM Sportsbook platforms to create pre-game and post-game betting programming, as well as distribution of highlights to users who have placed bets.

10:00 EDT Casper Sleep falls -11.9% - Casper Sleep is down -11.9%, or -$1.09 to $8.14.

10:00 EDT Varian rises 21.9% - Varian is up 21.9%, or $31.24 to $173.96.

10:00 EDT ADT Inc. rises 82.7% - ADT Inc. is up 82.7%, or $7.12 to $15.73.

09:47 EDT Leaf Group falls -7.2% - Leaf Group is down -7.2%, or -37c to $4.76.

09:47 EDT Eastman Kodak falls -13.0% - Eastman Kodak is down -13.0%, or -$2.84 to $19.01.

09:47 EDT Jernigan Capital rises 23.4% - Jernigan Capital is up 23.4%, or $3.28 to $17.29.

09:40 EDT ADT trading resumes

09:38 EDT Cinedigm announces distribution partnership with Littlstar - Cinedigm announced that the company has partnered with Littlstar, "one of the fastest-growing and most popular streaming services," to distribute Cinedigm's portfolio of linear and video-on-demand channels. Littlstar is the leading provider of premium streaming film & television content to the gaming ecosystem, where it reaches over 100 million Sony PlayStation consoles, and also reaches hundreds of millions of additional streaming devices including Android TVs, mobile devices, and many more.

09:35 EDT ADT trading halted, volatility trading pause

09:32 EDT Sky Solar says court issues order on behalf of Hudson Solar Cayman - Sky Solar Holdings announced that on July 30, 2020 the Grand Court of the Cayman Islands, following an ex parte proceeding in which the Company was not permitted to appear, issued an order on behalf of Hudson Solar Cayman LP. The Order freezes certain of the Company's assets and appoints three receivers to manage the affairs of the Company's wholly owned subsidiary, Sky Solar Power, which is an intermediate holding entity under the Company. Under the Order, the Receivers have been instructed to protect the value of Sky Solar Power and prevent any diminution in its value, including by the granting of security over its assets, and they have been granted various powers to implement these instructions. The Order also prohibits the Company from taking any steps in relation to the term loan facility, as contemplated in the unsolicited tender offer of Square Acquisition Co., Square Limited, Japan NK Investment K.K., IDG-Accel China Capital L.P., IDG-Accel China Capital Investors L.P., Jolmo Solar Capital Ltd., CES Holding Ltd., Jing Kang, Bin Shi, Sino-Century HX Investments Limited, Kai Ding, TCL Transportation Holdings Limited, Esteem Venture Investment Limited, Mamaya Investments Ltd, Xanadu Investment, Abdullateef A. AL-Tammar, Development Holding Company Ltd., and Bjoern Ludvig Ulfsson Nilsson, as filed with the U.S. Securities and Exchange Commission by the Offer Group on July 6, 2020 and as amended and filed by the Offer Group on July 24, 2020 and July 27, 2020. The Order does not prohibit the Company from dealing with or disposing of its assets in the ordinary course of its business or with prior approval of either the Receivers or the Cayman Islands Court. Hudson sought the order in connection with the ongoing litigation between it and the Company in the Supreme Court of the State of New York with respect to the Amended and Restated Note Purchase Agreement dated July 15, 2016 between Hudson and certain of the Company's subsidiaries. The Company is vigorously contesting Hudson's claims in the New York Court. The Company intends to file papers with the Cayman Islands Court to seek a hearing among all parties to discharge the Order as soon as possible.

09:31 EDT Atossa Therapeutics receives approval to open study of AT-301 nasal spray - Atossa Therapeutics announced that it has received approval from the ethics committee to open a Phase 1 clinical study in Australia using Atossa's proprietary drug candidate AT-301, to be administered by nasal spray. All necessary approvals have now been obtained and enrollment is expected to begin in the next 30 days. AT-301 is being developed for nasal administration in patients immediately following diagnosis of COVID-19 but who have not yet exhibited symptoms severe enough to require hospitalization. It is intended for at-home use to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person's immune system can more effectively fight SARS-CoV-2 (coronavirus). Atossa also intends to conduct testing to determine whether AT-301 can be used as a prophylaxis to prevent or mitigate SARS-CoV-2; for example, as a daily preventative treatment for people at higher-risk, such as frontline workers, military, emergency medical professionals, and hospital personnel. The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups. Part A consists of two single-dose cohorts receiving either active therapy, AT-301B, or the placebo comparator AT-301A at two different doses. Part B is a multiple dose arm with cohorts receiving either AT-301A or AT-301B for 14 days at two different doses. The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of AT-301 administered via nasal instillation to healthy volunteers. Secondary objectives are to assess the incidence and severity of local irritation and bronchospasm following administration of AT-301 via nasal instillation. The study is being conducted in Australia.

09:29 EDT Genius Brands announces Rainbow Rangers Toys available at Walmart, Amazon - Genius Brands International (GNUS) announced the debut of the first toys from Fisher-Price, a division of Mattel, Inc. (MAT), for the hit original preschool series, Rainbow Rangers, now available at Walmart (WMT) stores across the U.S., Walmart.com and Amazon (AMZN). The "Team Rainbow Rangers" multipack features characters-Rosie Redd, Mandarin Orange, Anna Banana, Pepper Mintz, Bonnie Blueberry, Indigo Allfruit, Lavender LaViolette and Floof-from the popular Rainbow Rangers series, currently airing on Nick Jr. in the U.S., Nickelodeon Latin America, China's CCTV and other key territories around the world. Each unique and diverse character represents a superpower, including super strength, music power, animal whisperer, invisibility, super vision, super speed, micro-power! The launch of the Rainbow Rangers' toys will be supported by a comprehensive national advertising and promotional campaign, including television advertising, widespread social media and influencer programs, a customer appreciation initiative, new content, and more. As part of the launch initiative, Genius Brands will be issuing commemorative, limited edition, numbered and hand-signed lithographs featuring the Rainbow Rangers to the first 1,000 buyers to submit proof of in-store or online purchase. The lithographs will be accompanied by a hand-signed certificate of authenticity and embossed foil seal to be affixed to the multipack. Genius Brands will also offer an additional 2,500 customers, at no cost, hand-signed and numbered Certificates of Authenticity and embossed seals.

09:26 EDT Tyson Foods: Chicken business suffered biggest impact from COVID-19

09:25 EDT Virtu Financial expands analytics platform by offering TCA for FX Algos - Virtu Financial announced the continued expansion of its global TCA offering with the launch of a new analytics product dedicated to FX algorithmic execution. As consumers of its own products, Virtu incorporates first-hand learning into its Analytics tools that are designed to assist clients in analyzing their trading decisions. Drawing on Virtu's scale, execution and analytics expertise, the new addition to Virtu's FX TCA offering merges data from three distinct sources: FX benchmark data sourced from Virtu's market making business; Virtu's global, broker-neutral market impact model: FX Agency Cost Estimator; Direct connections to bank algo providers on behalf of clients that subscribe to the offering. This unique combination enables Virtu's FX TCA for Algo clients to enhance their understanding of algo performance and compare FX algo providers and strategies to help improve their execution outcomes.

09:21 EDT Tyson Foods: Alternative protein remains top growth priority

09:20 EDT Coastal Community Bank, Google collaborate for digital bank accounts - In order to provide the enhanced user experience our customers need and expect, Coastal Community Bank (CCB) announced that it is working with Google (GOOG, GOOGL) to introduce digital bank accounts, which will be available to its customers through Google Pay in 2021. Coastal Community Bank and Google will bring the best of our respective strengths together to benefit our customers with powerful financial tools. Coastal Community Bank will build the digital checking account on our existing banking infrastructure using our trusted financial and regulatory expertise. Google will provide front-end, intuitive user experiences and financial insights based on their experience in building great user experiences and highly scaled and secure infrastructure. These digital accounts will enable Coastal Community Bank to better serve its expanding footprint with helpful products that enable customers to easily manage their finances.

09:17 EDT Tyson Foods can't say how long COVID-19 impacts will last

09:15 EDT Tyson Foods expects ecommerce demand to remain elevated

09:14 EDT Ferroglobe announces listing transfer to the NASDAQ Capital Market - Ferroglobe has received approval from the NASDAQ Stock Market of the Company's request to transfer listing of its ordinary shares to the NASDAQ Capital Market from the NASDAQ Global Select Market. As previously disclosed, NASDAQ notified Ferroglobe in November 2019 that the Company was out of compliance with the minimum bid price requirement of NASDAQ listing rule 5550(a)(2), as the closing bid price for its shares had remained below $1.00 for more than thirty consecutive days. On transfer to the NASDAQ Capital Market, Ferroglobe receives an additional 180-day grace period, effective August 4, 2020, within which to regain compliance with the minimum closing bid price requirement for continued listing. The Company has given written assurance to NASDAQ that it intends to do so, if necessary, by means of a reverse stock split. The transfer is expected to take effect on at the start of trading on August 4, 2020. The Company's shares will continue to trade under the symbol "GSM". The NASDAQ Capital Market is a continuous trading market that operates in substantially the same manner as the NASDAQ Global Select Market, and listed companies must meet certain financial and corporate governance requirements to qualify for continued listing.

09:12 EDT Generex announces conference call to provide details on corporate initiatives - Generex Biotechnology announced that it will hold an investor conference call on Wednesday, August 26th at 9:00 am. During the call, Generex President & CEO Joe Moscato will discuss the company's new venture in telemedicine and remote patient monitoring that will be deployed in collaboration with its partnered clinics in Arizona and integrated physician network, providing near-term revenue model. Additionally, Mr. Moscato will provide an update on the Altucell acquisition. Joseph Moscato, Generex President & CEO said, "During this COVID-19 pandemic, the world has been disrupted and business has been significantly altered not only today, but into the future as well. This business transformation is especially important for the future of healthcare, where telehealth is finally being recognized as a solution for access to care. Insurers and government payers are adopting telehealth practices with reimbursements for remote patient care. For the last year, the Generex team has been evaluating a number of healthcare information technology solutions, and we are happy to have selected a partner in a new venture in telemedicine and remote patient monitoring that we plan to implement with our physician partners in Arizona clinics. With this technology offering and the re-launch of DME-IQ, we will also be positioned to activate our physician networks. Our new telemedicine venture will enable us to generate near-term revenues, build out our physician and patient networks, and establish a foundation for success in the technological future of healthcare. Throughout this pandemic, we have continued to move forward on our oncology program and the development of a SARS-CoV-2 vaccine based on the Ii-Key technology, and we have worked diligently to respond to the ever-changing market conditions we are experiencing by launching operating and financing initiatives. Over the next few weeks leading to the shareholders' call, we will provide additional information in separate announcements outlining the details of these new initiatives including the telehealth venture, the ALTuCell acquisition, and the closing of three funding instruments. I look forward to speaking with shareholders on August 26th."

09:10 EDT Beyond Meat expands club store distribution with BJ's Wholesale, Sam's Club - Beyond Meat is working to increase accessibility to plant-based meat through the development of new sales channels, including club and convenience stores. The company, which offers an 8-pack of its flagship Beyond Burger, first broke into the club channel last year at Costco. This summer, Beyond Meat added partnerships with BJ's Wholesale and Sam's Club, unlocking partnerships with three major club stores. Beyond Meat was the first plant-based meat option that Sam's Club explored via an initial test earlier this year at all locations. Following a strong, positive response from consumers, Sam's chose to make the Beyond Burger a permanent offering. After seeing a growing interest in plant-based options, BJ's Wholesale evaluated several options and ultimately chose to offer its members Beyond Meat, a leader in the space.

09:09 EDT R1 RCM completes acquisition of RevWorks - R1 RCM (RCM) announced it has completed the acquisition of the Cerner (CERN) RevWorks services business and commercial, non-federal client relationships. The combination of R1 and RevWorks is expected to provide enhanced revenue cycle capabilities and expertise to clients and new prospects, helping drive sustainable financial improvements for providers while improving their patients' overall experience. Significant progress has been made toward seamlessly integrating R1's technology-enabled services platform and Cerner's software.

09:08 EDT Arcutis Biotherapeutics announces publication of results from ARQ-151 trial - Arcutis Biotherapeutics announced that The Journal of Drugs in Dermatology has published positive results from a Phase 1/2a trial of its investigational drug topical roflumilast cream for the treatment of chronic plaque psoriasis. The article has been published in the August 2020 issue of the journal. These results demonstrate that ARQ-151 was safe and highly effective at doses of 0.5% and 0.15%, and represents a potential novel once-daily topical therapy for the treatment of chronic plaque psoriasis. Roflumilast cream is a once-daily, highly potent, selective phosphodiesterase-4 inhibitor being developed for chronic plaque psoriasis. Arcutis is currently conducting a Phase 3 clinical program with topical roflumilast cream, including two ongoing pivotal Phase 3 clinical trials. The company anticipates topline data from the Phase 3 studies in the first half of 2021. The Phase 1/2a study assessed the safety and efficacy of once-daily roflumilast cream 0.5% and 0.15% in patients with chronic plaque psoriasis. The study enrolled a single-dose, open-label Phase 1 cohort, and a 28-day, double-blinded Phase 2a cohort. Patients had chronic plaque psoriasis of greater than 6 months' duration with less than or equal to5% body surface area involvement. Outcomes included safety and efficacy at week 4. For Cohorts 1 and 2, adverse events were similar between active arms and vehicle. Treatment-related events were confined to the application site, with no difference between active and vehicle. No patient discontinued treatment due to adverse events. The primary efficacy endpoint was met for both roflumilast cream doses: TPSSTPA improvement at week 4 was statistically significant for roflumilast 0.5% and 0.15% versus vehicle; significance was reached as early as 2 weeks. For both roflumilast cream doses, 66% to 67% improvement from baseline was observed at week 4, without reaching a plateau, versus 38% improvement for vehicle.

09:07 EDT Truist Financial: SunTrust Robinson Humphrey, BB&T Capital now integrated - Truist Financial announced that its corporate and investment banking businesses, SunTrust Robinson Humphrey and BB&T Capital Markets, have integrated and are now doing business as Truist Securities.

09:06 EDT Regions Financial appoints Paula Drake as Chief Communications Officer - Regions Bank announced that it has named Paula Drake executive vice president and Chief Communications Officer. Drake will report to Chief Human Resources Officer Dave Keenan and lead the bank's Corporate Communications team responsible for internal and external communications, market public relations, content publishing and video production. Drake joins Regions from Home Depot, where she most recently served as corporate and executive communications director.

09:05 EDT Triumph Group to sell composites operations to Arlington Capital Partners - Triumph Group (TGI) announced a definitive agreement to sell its composites operations to Arlington Capital Partners. Included in the sale are the Triumph Aerospace Structures composites locations in Milledgeville, Georgia and Rayong, Thailand. The operations cover approximately 800 thousand square feet of factory space and employ approximately 600 people. The composites business provides structural and engine composite fabrications and assemblies across commercial, business jet, and defense platforms. Key programs supported by the sites include Boeing (BA) 787, 777 and V-22, Airbus (EADSY) A320, A330 and A350, Embraer (ERJ) E-2, Northrop Grumman (NOC) Global Hawk, as well as the Gulfstream G650/700. The transaction is subject to customary closing conditions and is expected to close in Triumph's second quarter of FY21. Following the close of the transaction, the business will retain its management, technical and supporting staff, and will continue operations at the current facilities.

09:04 EDT Citi selected to provide custody, tax services by Cavali - Citi has been selected to provide custody and tax services by Cavali., the central securities depository, or CSD, for the Lima Stock Exchange for $6B of dual-listed securities. The dual listing platform of the Lima Stock Exchange and Cavali provides investors with access to international securities.

09:03 EDT Luckin Coffee directors Jie Yang, Ying Zeng resign - Luckin Coffee announced the following: The Company received a letter of resignation on August 3, 2020 from Ms. Jie Yang and Ms. Ying Zeng, respectively, under which Ms. Yang and Ms. Zeng notified the Company of their resignations from the Board of Directors of the Company, effective immediately.

09:00 EDT Cardinal Resources presents Quarterly activities report - Cardinal Resources is pleased to present its Quarterly activities report for the period ended 30 June 2020. HIGHLIGHTS: On March 16, 2020 the Company advised that it had received notification from Nord Gold SE that it had acquired a relevant interest of 19.9% of the shares in Cardinal, and further advised that Nordgold had provided a non-binding indicative and conditional proposal to acquire all the issued capital of Cardinal that it did not already own for AU$0.45775 per share in cash. On March 30, 2020 the Company updated its shareholders and provided commentary as to how the Company is managing the current COVID-19 pandemic. On May 4, 2020 the Company announced an update on permitting approvals and COVID-19 impacts on the Company's progress. On June 5, 2020 the Company announced that the senior secured credit facilityhad been assigned from Sprott Private Resource Lending, L.P. to the Ghana Infrastructure Investment Fund, a Ghana Government owned infrastructure investment vehicle. On June 16, 2020 the Company responded to media speculation in Ghana and advised that the Company continued strategic discussions with banks, financiers and other parties which continued to show interest in bringing the Namdini Project into production with a view to maximising economic outcomes. Whilst discussions in relation to any potential transaction remain ongoing, at that time no agreement had been entered into in relation to any transaction. On June 18, 2020 the Company announced the recommended all-cash takeover offer of Cardinal Resources by Shandong Gold Mining Co. Cardinal entered into a Bid Implementation Agreement with Shandong Gold, pursuant to which Shandong Gold agreed to acquire 100% of the issued and outstanding ordinary shares in Cardinal at a price of AU$0.60. Proposed implementation by way of an off-market takeover offer with a 50.1% minimum acceptance condition. The Board of Cardinal unanimously recommended acceptance of the Shandong Gold offer in the absence of a superior proposal. On July 7, 2020 the Company announced that it had raised AU$11,960,000 as a result of the issue of 26,000,000 fully paid ordinary shares to Shandong Gold in accordance with the terms of the Bid Implementation Agreement. On July 15, 2020 Cardinal received an unconditional on-market takeover offer at AU$0.66 per share from Nordgold. Having regards to the unsolicited nature of the takeover bid and the provisions of the Bid Implementation Agreement with Shandong Gold, the Board of Cardinal recommended a 'take no action' at the time in relation to the Nordgold takeover bid. On July 20, 2020 the Company advised that its Namdini Mining Licence had officially received Sovereign Parliamentary Ratification in Ghana. On July 22, 2020 the Company advised that it had received a revised and improved proposal for an off-market takeover from Shandong Gold, pursuant to which Shandong Gold will offer to acquire all of the shares in Cardinal it does not presently own at a cash price of $0.70 per share. On July 27, 2020 the Company, after careful consideration of the Revised Shandong Gold Offer and Nordgold's unconditional on-market offer for Cardinal, Cardinal's Board of Directors, unanimously recommended that Cardinal shareholders; ACCEPT the Revised Shandong Gold Offer; and REJECT the Nordgold Bid. On July 30, 2020 the Company advised that it had entered into a deed with each Shandong Gold Mining Co., Limited and Shandong Gold Mining Co., Ltd, to amend the Bid Implementation Agreement.

08:55 EDT Ideal Power enters into early warrant exercise transaction - Ideal Power entered into an early warrant exercise transaction with certain of the Company's Series A warrant holders through a letter agreement between the Company and such Series A warrant holders, pursuant to which the Company will raise approximately $2.7M in gross proceeds. A portion of the proceeds from the transaction will be utilized to fund commercialization and development of the Company's patented Bi-directional, Bi-polar Junction Transistor semiconductor technology. As an incentive for the Series A warrant holders to exercise their Series A warrants early, the holders will be issued new Series C warrants to purchase up to an aggregate of 705,688 shares of the Company's common stock, at an exercise price of $8.90 per share, through a private placement. Craig-Hallum Capital Group is acting as the exclusive placement agent for this transaction. The Series C warrants to be issued in this transaction have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements. The issuance of the Series C warrants is exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act. Ideal Power has agreed to file a registration statement with the SEC covering the resale of the shares of common stock underlying the Replacement Warrants.

08:53 EDT Research Frontiers' smartglass technology licensed to Daimay - Glare is a major safety and comfort issue for drivers and passengers. Imagine driving down the road, turning into the sun, and having your sun visor automatically and instantly darken to block the glare. This product is currently being developed in Michigan by Daimay North America Automotive using patented SPD-Smart light-control film technology invented by Research Frontiers and licensed to Daimay. The visor uses a light sensor to automatically and dynamically adjust the sun visor to deal with changing light and glare conditions. SPD-Smart light control film, invented and patented by Research Frontiers, is a key component in SPD-SmartGlass products. This film allows users to instantly, precisely and uniformly control the shading of glass or plastic products, either manually or automatically at the touch of a button. Products using Research Frontiers' smart glass technology are being used in tens of thousands of cars, aircraft, yachts, trains, homes, offices, museums and other buildings.

08:50 EDT Everi launches slot content at Borgata Online Casino, BetMGM, Party Casino - Everi Digital (EVRI) has partnered with ROAR Digital LLC, a joint venture created by MGM Resorts International (MGM) and GVC Holdings, to launch three of its long-time player popular three-reel mechanical titles on Borgata Online Casino, BetMGM, and Party Casino New Jersey. Smokin' 777, Meltdown, and Double Ruby are available for play now on these market leading brands for online real-money gaming in New Jersey. In addition, Everi Digital will launch Hot Spot 777, an exclusive title for GVC Holdings Plc. in August 2020. Additional titles are expected to follow this initial launch.

08:48 EDT Atlantica Yield closes $115M green exchangeable notes - Atlantica Sustainable Infrastructure successfully closed an unsecured $115M aggregate principal amount Green Exchangeable Notes. Atlantica previously announced the closing of the initial $100M in Green Exchange Notes on July 17, 2020 and subsequently closed an additional $15M on July 29, 2020 pursuant to an over-allotment option granted to the initial purchasers. The new green financing matures in 2025 and bears interest at a rate of 4.00% per annum, payable semiannually in arrears. The initial exchange price is $34.36 per ordinary share. The notes and related guarantee were offered to only qualified institutional investors pursuant to Rule 144A under the Securities Act of 1933. Atlantica expects to use the proceeds to finance its accretive growth opportunities in accordance with its Green Finance Framework requirements available on its website. The issuance was made with the support of a Second Party Opinion delivered by Sustainalytics, also published on Atlantica's website. This is the third green financing closed by Atlantica in 2020. In April, the Company closed a non-recourse green project finance that resulted in net proceeds for Atlantica of approximately $143M. Additionally, in the second quarter of 2020, the Company closed a Green Private Placement of approximately $320M. These Green Senior Secured Notes denominated in Euros have a 6-year tenor and bear interest at a rate of 1.96% per annum.

08:45 EDT Bionano Genomics announces publication on Bionano's Saphyr - Bionano Genomics announced the publication of the first study to utilize its genome imaging system, Saphyr, for the analysis of structural variants in lung cancer and metastases. The study, published in Translational Lung Cancer Research by a team of scientists from Fudan University Shanghai Cancer Center and Shanghai Medical College, analyzed SVs using both short-read next-generation sequencing technology and Bionano's Saphyr system on a primary lung squamous cell carcinoma sample, and on matched metastases from lymph node and pulmonary vein. The study showed that Saphyr outperformed NGS-based methods in the detection of structural variants to characterize the genetic heterogeneity between the primary tumor and the matched metastases. Of 1026 large SVs detected on average by Saphyr in each of the tumor types, the NGS-based methods failed to detect an average of 77%. Saphyr identified 52 SVs shared between the metastases, while no shared SVs were found by NGS-based methods. The study authors stated that Saphyr is more capable of detecting large and complex SVs, without the computational and bioinformatic challenges that come with SV calling from NGS data. They found that like with point mutations and small insertions/deletions detected with NGS, SVs make up a large part of tumor heterogeneity. The authors describe that the combination of NGS and Saphyr allowed for a more comprehensive understanding of the variation between primary tumor and metastases, with Saphyr making up for the inability of NGS to detect large SVs.

08:37 EDT Cowen Group leads $10M Series A financing round in Kyber Data Science - Kyber Data Science announced a $10M Series A financing round led by Cowen and Ian McKinnon, founder of Sandia Holdings LLC. Mr. McKinnon has joined Kyber's board of directors, effective upon closing of the investment. Kyber is focused on developing and selling unique and proprietary datasets across a variety of sectors to institutional investors and corporations. Most recently, Kyber unveiled a nationally-representative health care claims and electronic medical records data product for the institutional investor that enables timely and accurate analyses across health care subsectors including drug, medical device, diagnostics, and facilities companies. Transaction-level data allow customers to develop a large number of key performance indicators, and drive granular insights into the intricacies of product revenue and disease dynamics.

08:35 EDT MyoKardia doses first patient in Phase 3 VALOR-HCM trial of mavacamten - MyoKardia announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial. VALOR-HCM will enroll individuals with obstructive hypertrophic cardiomyopathy who have been referred for septal reduction therapy and are refractory to current therapeutic options, including those who have severe symptoms. VALOR-HCM is designed to provide direct clinical evidence of mavacamten's ability to mitigate the need for invasive SRT procedures and is the first of several potential studies planned by MyoKardia to expand on the existing body of evidence supporting mavacamten's use as a potential backbone therapy for HCM. VALOR-HCM is being conducted in partnership with Cleveland Clinic C5Research, an academic research organization, with participation from approximately 15 HCM specialty centers in the U.S. with well-recognized expertise in SRT procedures. HCM is the most common genetic cardiomyopathy, estimated to affect one in every five hundred people. It is a chronic, progressive condition in which the heart muscle thickens due to hypercontractility caused by excess engagement of myosin, a primary motor protein of the heart. In the obstructive form of HCM, the wall of the septum thickens and may block the flow of blood from the left ventricle to the aorta. Mavacamten is the first agent designed to improve the underlying pathophysiology of HCM and has been shown in MyoKardia's past clinical studies to reduce the obstruction of the left ventricle to below the threshold for guideline-recommended SRT interventions. In May, MyoKardia announced positive results from the pivotal Phase 3 EXPLORER-HCM clinical trial of mavacamten in patients with symptomatic, obstructive HCM and the company plans to submit a New Drug Application to the U.S. Food and Drug Administration for regulatory approval in the first quarter of 2021. Data from the VALOR-HCM study will not be part of the initial registration package but may provide supplemental data which could potentially expand the labeled benefit of mavacamten to a population of patients with severe symptoms of obstructive HCM who are refractory to maximal available medical therapy. VALOR-HCM is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study of patients with symptomatic, obstructive HCM who meet guideline criteria for septal reduction therapy and have been referred for an invasive procedure. Throughout the course of the study, patients may continue on background heart failure-related medications without change. The study is expected to enroll approximately 100 patients randomized on a 1:1 basis to receive mavacamten or placebo. VALOR-HCM includes three treatment periods over 128 weeks: a 16-week placebo-controlled period, a 16-week active treatment period where all patients will receive mavacamten and a 96-week long-term extension period where all patients will continue to receive mavacamten. Patients receiving mavacamten will start at a dose of 5mg with subsequent echocardiographic assessments for dose adjustment based on the reduction of left ventricular outflow tract gradient, a measure of LVOT obstruction. Dose may be up-titrated for those whose gradient remains above 30mmHg, and whose left ventricular ejection fraction remains at or above 50 percent. Throughout the study, all dose adjustments will occur in a blinded manner and doses may be down-titrated for safety at any time. The primary endpoint will be a composite of 1) the number of subjects who decide to proceed with SRT prior to or at Week 16 and 2) the number of subjects who remain SRT-guideline eligible at Week 16 in the mavacamten group compared with the placebo group. An interim analysis is planned after 50 subjects have completed treatment through Week 16 to assess efficacy. Secondary endpoints include assessment of the outcomes at Week 32 compared with Week 16 to demonstrate persistence of benefit for subjects in the mavacamten group. The study will also measure changes in the LVOT gradient, a direct measure of obstruction of the outflow from the left ventricle, as well as biomarkers, including NT-proBNP and cardiac troponin. Safety assessments include monitoring of adverse events and concomitant medications, safety laboratory assessments, physical examinations, vital sign measurements, cardiac/activity monitoring, and electrocardiograms. Total study duration will be 138 weeks, including a two-week screening period and an eight-week post-treatment follow-up.

08:31 EDT Flushing Financial, Empire Bancorp continue merger discussions - Flushing Financial Corporation (FFIC), parent company of Flushing Bank, and Empire Bancorp (EMPK), announced that they have each advised the other they will not exercise their respective rights to terminate the Agreement and Plan of Merger, dated October 24, 2019, as amended, as would otherwise be permitted after July 31st by the terms of the merger agreement. Flushing and Empire are engaged in discussions for a longer term extension of time to complete the merger.

08:25 EDT Pacific Biosciences, Asuragen collaborate to develop assays - Pacific Biosciences of California and Asuragen announced their clinical research collaboration aimed at developing molecular assays based on PacBio's Single Molecule, Real-Time Sequencing technology. The initial focus of the collaboration will be on research in support of assay development for the carrier screening market. Several of the most common carrier genes for autosomal recessive and X-linked conditions are either technically challenging or inaccessible to amplify and sequence, leading to incomplete coverage and convoluted workflows spread over multiple platforms. Through this collaboration, Asuragen scientists will develop assays that combine the company's AmplideX PCR technology for enriching hard-to-amplify sequences with PacBio SMRT Sequencing, a highly accurate long-read sequencing technology with a unique ability to represent all regions of the genome and to detect any kind of structural or other variation. Scientists at Asuragen will develop assays for PacBio's Sequel Systems using Asuragen's AmplideX PCR technology. AmplideX products are designed to solve testing needs in inherited genetic disorders through easy-to-run assays and optimized workflows that deliver best-in-class performance. Assays will make use of PacBio's HiFi long reads, an approach incorporating multiple passes of the same molecule to create a highly accurate consensus sequence.

08:22 EDT Waisman Biomanufacturing partners with Heat Biologics on COVID vaccine for trial - Waisman Biomanufacturing at the University of Wisconsin-Madison announced it is partnering with Heat Biologics to produce a COVID-19 vaccine for phase 1 and phase 2 clinical trials. Phase 1 trials could begin in early 2021 and UW-Madison may be a trial site, the group said. "Waisman Biomanufacturing's mission is to advance novel vaccines and therapeutics into early human clinical trials. We are very excited to be able to offer what we have to this cause," says Carl Ross, managing director of Waisman Biomanufacturing, part of the Waisman Center. "In addition to its potential as a standalone COVID-19 vaccine, we believe this platform holds enormous promise in combination with other vaccines under development and in clinical trials by boosting the patient's T-cell immunity," added Jeff Wolf, CEO of Heat. Reference Link

08:19 EDT Melinta Therapeutics appoints Christine Ann Miller as president, CEO - Melinta (MLNT) Therapeutics announced that its Board of Directors has appointed Christine Ann Miller as President and CEO and member of the board, effective August 3, 2020. In April of this year, Melinta became privately owned by affiliates of healthcare investment firm Deerfield Management Company, resulting in a well-financed and strongly positioned hospital-focused company. Melinta expects to build upon its existing platform and enhance its world-class antibiotics portfolio with additional products that address therapeutic areas of critical need. Miller is a global pharmaceutical veteran with more than 20 years of experience in life sciences. Most recently, Ms. Miller led the global and U.S. product portfolio for Sandoz, a $10 billion division of Novartis (NVS). With the appointment of Ms. Miller and effective as of the commencement date of Ms. Miller's employment, Jennifer Sanfilippo will step down from her role as Interim CEO and Director of Melinta and resume her role as SVP and General Counsel.

08:16 EDT ATIF Holdings signs multimedia services contracts - ATIF Holdings Limited has signed contracts with more than 20 renowned corporate clients to provide multimedia services. Some of the corporate clients are China and Global Top 500 companies. Pursuant to the contracts LGC signed with the clients, LGC will produce promotional videos, documentaries, internet broadcast programs and product marketing related multimedia production services for over 20 renowned corporate clients such as COFCO Property, Industrial and Commercial Bank of China, China Vanke, Agile Property and Evergrande, which are ranked among China and Global Top 500 enterprises.

08:13 EDT Day & Ross selects PowerFleet for solar powered tracking technology - PowerFleet announced it will be outfitting a large portion of the full Day & Ross trailer fleet with PowerFleet's LV-500 solar tracking solution and the PowerFleet LV-710 Freight Camera. As one of the largest transportation companies in Canada, with more than 8,000 employees, drivers, and owner operators, Day & Ross has grown to be a critical player in transportation and logistics in North America. With a focus on efficient and effective equipment utilization, Day & Ross intends on deploying the PowerFleet's LV-500 product across a fleet of over 3,000 trailers to optimize the management of shipping lanes and ensure cost effective operations; a portion of these trailers will also be equipped with the PowerFleet LV-710.

08:12 EDT Cerence introduces Cerence Reader - Cerence announced Cerence Reader, a new product based on its neural text-to-speech offerings that brings a natural, expressive voice into the car to read the news to drivers on the go. Cerence Reader leverages advances in AI and processing hardware to bring unprecedented levels of human-like speech to the car. Nearly indistinguishable from a human voice, Cerence Reader features long-form reading capabilities, including natural pausing and breathing, and automatic prediction of the appropriate reading style and emotional tone based on content, context, and category of news, including current events, sports, or documentary-style pieces. Cerence Reader can also be adopted for additional scenarios beyond news reading, such as audiobooks, language learning and more.

08:11 EDT Provident Financial completes merger with SB One Bancorp - Provident Financial Services (PFS) announced that the acquisition of SB One Bancorp (SBBX) and its subsidiary, SB One Bank, closed effective July 31, 2020. Under the terms of the merger agreement, each outstanding share of SB One common stock will be exchanged for 1.357 shares of Provident common stock together with cash in lieu of any fractional shares. The combined organization will have approximately $12 billion in assets and will rank as the 3rd largest bank headquartered in New Jersey. The merger brings together two high-performing companies with complementary geographies and business lines.

08:11 EDT Freshpet appoints Thembi Machaba as SVP, human resources - Freshpet (FRPT) announced the appointment of Thembi Machaba as Senior Vice President of Human Resources, effective August 1, 2020. Ms. Machaba will lead Freshpet's Human Resources organization and report directly to Billy Cyr, CEO Prior to joining Freshpet, she was Vice President Global Human Resources & Organization Effectiveness at Molson Coors Beverage Company (TAP).

08:09 EDT TriSalus acquires Dynavax's SD-101 Oncology Program in purchase agreement - Dynavax Technologies and TriSalus announced that they have entered into an asset purchase agreement under which TriSalus has purchased SD-101, a proprietary investigational, second-generation, Toll-like receptor 9 agonist CpG-C class oligodeoxynucleotide, which has been studied in advanced cutaneous melanoma, and is currently in clinical trials for high risk Stage II/III breast cancer. Purchased assets include SD-101-related Intellectual Property, clinical data, regulatory filings, and inventory. Under the terms of the agreement, TriSalus will pay Dynavax $5M upfront, an additional cash payment of $4 million on December 30, 2020, for reimbursement of research and development expenses, up to an additional $250 million upon the achievement of certain development, regulatory, and commercial milestones, and low double-digit royalties based on potential future net sales.

08:07 EDT Dasan Zhone appoints Charlie Vogt as president, CEO - DASAN Zhone Solutions announced it has appointed Charlie Vogt as president, CEO and director effective August 1. Vogt joins DZS from ATX Networks, where he remains a member of the board. He succeeds Yung Kim, who has retired after a successful 40-year international telecommunications career and nearly four years at the helm of DZS. Vogt was most recently president and CEO of ATX Networks, a leader in broadband access and media distribution, where he led the company through extensive transformation and growth.

08:05 EDT Jernigan Capital to be acquired by NexPoint in $900M all-cash transaction - Jernigan Capital announced that it has entered into a definitive merger agreement with an affiliate of NexPoint Advisors under which it will be acquired by NexPoint in an all-cash transaction valued at approximately $900M, including debt and preferred stock to be assumed or refinanced. The agreement has been unanimously approved by the company's board of directors. The transaction was recommended to the company's board by a transaction committee consisting of all directors established to evaluate the transaction. Under the terms of the merger agreement, holders of JCAP's common stock and holders of units of operating company interests in Jernigan Capital Operating Company will receive $17.30 per share/unit in cash. This represents a 30% premium over the 90-day volume-weighted average share price ending July 31 and a 23% premium over the July 31 closing share price. Holders of the company's Series B preferred stock will receive cash equal to $25.00 per share plus all accrued dividends up to, but excluding, the date the merger is consummated. The transaction, which is currently expected to close in the Q4, is subject to customary closing conditions, including the approval of JCAP's stockholders, who will vote on the transaction at a special meeting on a date to be announced. The transaction is not contingent on receipt of financing by NexPoint. Under the merger agreement, Jernigan Capital will discontinue its regular quarterly dividends.

08:05 EDT Lipocine announces peer reviewed publication of LPCN Liver Fat Study - Lipocine announced the peer reviewed publication of LPCN 144 Liver Fat Study results in Hepatology Communications. LPCN 1144 is an oral prodrug of bioidentical testosterone. The study aims were: to determine the prevalence of NAFLD within a population of hypogonadal males and the relationship of circulating testosterone levels with the presence and severity of NAFLD, to evaluate the impact of LPCN 1144 on hepatic steatosis and markers of liver injury in hypogonadal men, and to assess the safety and tolerability of LPCN 1144 in this population. The company expects results from its on-going Phase 2a LiFT clinical study in biopsy confirmed NASH subjects by the end of 2020.

08:04 EDT Chipotle launches responsibly sourced line of Chipotle Goods - Chipotle Mexican Grill announced it is launching a responsibly sourced line of Chipotle Goods, made with organic cotton, and branded accessories available exclusively for Chipotle Rewards members. The collection will feature an open-looped line of Chipotle apparel, dyed with upcycled avocado pits from its restaurants as well as branded unisex gear. All profits from the collection will go toward supporting organizations that are focused on making fashion or farming more sustainable. Chipotle Rewards' 15M members will have first access to the collection by using a special password shared via email. The Chipotle Goods line will be available for the public beginning August 4.

08:02 EDT Biohaven Pharmaceutical enrolls first patients in Healey ALS platform trial - Biohaven Pharmaceutical enrolled the first patients in the Healey ALS Platform Trial, which is evaluating the efficacy of three treatments including verdiperstat in people with amyotrophic lateral sclerosis or ALS. Verdiperstat is a potential first-in-class, brain-penetrant, selective inhibitor of myeloperoxidase in development by Biohaven for the treatment of neurodegenerative diseases, including ALS and multiple system atrophy. The Healey ALS Platform Trial is aimed at accelerating the identification of effective new treatments. The study's primary efficacy endpoint will measure the change in disease severity from baseline to week 24 on the ALS Functional Rating Scale-Revised in patients receiving treatment versus placebo. Secondary endpoints will include change in respiratory function, muscle strength, and survival.

07:56 EDT Dish selects Tucows as technology partner, acquires Ting Mobile assets - DISH Network Corporation (DISH) and Tucows Inc. (TCX) announced that DISH has chosen Tucows as a technology partner for its retail wireless business. With a history of digital innovation, Tucows has made the strategic decision to offer Mobile Services Enabler solutions, beginning with DISH. As part of this agreement, DISH has also acquired Ting Mobile assets, including customer relationships. Effective August 1, 2020, most Ting Mobile customers across the U.S. became customers of DISH. These customers will continue to use their current phones and will enjoy the same rates and excellent customer experience. As with DISH's recently acquired Boost customers, these Ting Mobile customers will have access to the new T-Mobile network. In mobile, Tucows will focus on growing its MSE business, delivering a wide range of functions including billing, activation, provisioning, and funnel marketing to mobile providers. Tucows provides leading enablement platforms in domain registration and fiber-to-the-home. DISH is now the first Tucows mobile technology customer.

07:54 EDT DraftKings launches Best Ball, $3M NFL tournament - DraftKings announced it is expanding its daily fantasy sports offerings to include the game variant Best Ball, with snake drafts. DraftKings also announced a $3M marquee tournament ahead of the 2020 NFL season, with a $1M top prize. As DraftKings' first foray into a season-long product, Best Ball maintains fans' connection to the DraftKings' fantasy sports experience, while answering to a more nostalgic, season-long form. The streamlined draft format removes traditional DFS roster management, enabling customers to lock in player selections at the start of the season. As major U.S. sports leagues continue to return to the national stage, Best Ball furthers DraftKings' reputation as being in-tune with the American sports fan, and offers customers a new opportunity to engage with friends and family in the absence of in-person events and gatherings. Across sports and unique to the game, Best Ball involves a draft process known as a "snake draft" where pick order is reversed for each individual round. Recognized as the preferred way to draft among seasoned DFS players, an overwhelming 92% of respondents in a recent DraftKings consumer-led study reported high interest in engaging with the format. Currently available only for fantasy football, Best Ball will soon be available for DraftKings' fantasy basketball and fantasy hockey as well, offering customers the opportunity to engage with daily snakes, sit-and-go's, and larger, prized season tournaments.

07:52 EDT Hookipa Pharma announces issuance of U.S., European patents - HOOKIPA Pharma announced that both the United States Patent and Trademark Office and the European Patent Office have issued patents covering HOOKIPA's proprietary replicating arenavirus technology. The patents are granted to the University of Geneva. HOOKIPA has exclusively licensed these patents from the University. The patent claims cover current product candidates based on HOOKIPA's replicating arenavirus platform technology, including the Company's lead oncology product candidates HB-201 and HB-202. These programs are currently in clinical development for the treatment of Human Papillomavirus 16-positive cancers. In addition to the replicating arenavirus platform patents, the USPTO recently granted a patent specifically related to HOOKIPA's HB-201 and HB-202 product candidates, which are two different replicating arenavirus-based vectors encoding the same E7/E6 fusion protein. The patent protection for HB-201 and HB-202 conferred by these platform and product-specific patents extends to 2037 in the United States and 2035 in Europe.

07:50 EDT Primoris announces solar award valued over $60M - Primoris announced two new solar awards with a combined value over $60M. The contracts were secured by the Power, Industrial, & Engineering segment. The awards are for the engineering, procurement, and construction of utility-scale solar facilities in the South. The scope of work includes foundations, electrical, mechanical, and civil construction. Work will commence in the third quarter of 2020, and completion is expected in the third quarter of 2021.

07:49 EDT Global Payments business signs multi-year payments agreement with TD Bank Group - Global Payments (GPN) announced that TSYS, its issuer solutions business, has signed a multi-year payments agreement with TD Bank Group, including TD Bank in Canada and TD Bank (TD) in the United States. TD is the sixth largest bank in North America, serving more than 26M customers and ranks as one of the leading online financial services firms with more than 14M active digital customers. As part of the agreement, TSYS will continue to provide a range of processing and support services for TD Bank's consumer and commercial card portfolios. TD Bank has utilized TSYS' payments processing platform since 2005. Terms of the agreement were not disclosed.

07:45 EDT Minerva to collect royalty on seltorexant sales after opt out of Janssen deal - On July 1, 2020, the Company announced that it exercised its right to opt out of its agreement with Janssen Pharmaceutica (JNJ) for the future development of seltorexant. As a result, the Company will collect a royalty on worldwide sales of seltorexant in all indications in the mid-single digits, with no financial obligations to Janssen. "With respect to seltorexant, the decision to opt out of our agreement with Janssen at this stage of the program enables us to retain a meaningful financial interest in the future revenue stream of a compound with significant commercial potential while eliminating the Company's financial obligations to a substantial Phase 3 program encompassing major depressive disorder and insomnia," said Dr. Luthringer. "Furthermore, opting out will help align our human and financial resources with our primary focus on defining a path to approval of our lead compound, roluperidone."

07:37 EDT Otonomy enters license agreement with Kyorin for compound in OTO-6XX program - Otonomy announced an exclusive license agreement with KYORIN Pharmaceutical that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound for the treatment of sensorineural hearing loss. Under the terms of the agreement, Otonomy will make an upfront payment to Kyorin as well as success-based milestone payments and royalties on worldwide net sales of a product containing the patent-protected compound. Otonomy is formulating the compound utilizing the company's proprietary technology to provide sustained drug exposure in the inner ear following a single local administration.

07:35 EDT Tyson: COVID-19 challenges to increase operating costs for remainder of 2020 - The company said, "For fiscal 2021, USDA indicates domestic protein production should increase approximately 1% from fiscal 2020 levels. The following is a summary of the outlook for each of our segments, as well as an outlook for capital expenditures, net interest expense, liquidity and tax rate for fiscal 2021. COVID-19 - We continue to proactively manage the company and its operations through this global pandemic. Given the nature of our business, demand for food and protein may shift amongst sales channels and experience disruptions, but over time we expect worldwide demand to continue to increase. We are experiencing multiple challenges related to the pandemic. These challenges are anticipated to increase our operating costs and negatively impact our volumes for the remainder of fiscal 2020 and into fiscal 2021. Operationally, we have faced and expect to continue to face capacity utilization slowdowns in production facilities from team member absenteeism and choices we make to ensure team member health and safety. The lower levels of productivity and higher costs of production we have experienced will likely continue until COVID-19 is better understood and its impacts diminish. Each of our segments has also experienced a shift in demand from foodservice to retail; however, the volume increases in retail have not been sufficient to offset the losses in foodservice and as a result, we expect decreases in volumes in the last quarter of fiscal 2020 in our Chicken and Prepared Foods segments. We cannot currently predict the ultimate impact that COVID-19 will have on our short- and long-term demand, as it will depend on, among other things, the severity and duration of the COVID-19 crisis. Our liquidity is expected to be adequate to continue to run our operations and meet our obligations as they become due. Due to the inability to reasonably quantify the total impact of COVID-19 to our operations, we are not currently providing segment adjusted operating margin guidance. Beef - USDA projects domestic production will increase approximately 3% in fiscal 2021 as compared to a COVID-19 impacted fiscal 2020. For fiscal 2021, we also expect ample supplies in regions where we operate our plants. Pork - USDA projects domestic production will increase approximately 1% in fiscal 2021 as compared to a COVID-19 impacted fiscal 2020. Chicken - USDA projects a relatively flat to slightly increased outlook for chicken production in fiscal 2021 as compared to fiscal 2020. Prepared Foods - We will continue to be responsive to changes in consumer behavior as a result of the impacts of COVID-19 as we move into fiscal 2020. nternational/Other - We expect improved results from our foreign operations in fiscal 2021. Capital Expenditures - For fiscal 2020, we expect capital expenditures to be approximately $1.2B with a similar amount expected in fiscal 2021. Capital expenditures include spending for production growth, safety, animal well-being, infrastructure replacements and upgrades, and operational improvements that are expected to result in production and labor efficiencies, yield improvements and sales channel flexibility. Net Interest Expense - We expect net interest expense to approximate $470M for fiscal 2020 and $440 million for fiscal 2021. Liquidity - We expect total liquidity, which was approximately $3.1B at June 27, 2020, to remain above our minimum liquidity target of $1B. Tax Rate - We currently expect our adjusted effective tax rate to be around 23% in fiscal 2020 and fiscal 2021."

07:35 EDT Members of COVID R&D Alliance enroll first patients in I-SPY COVID Trial - Members of the COVID R&D Alliance, AbbVie (ABBV), Amgen (AMGN), and Takeda Pharmaceutical Co. (TAK), announced the first patients enrolled in the I-SPY COVID Trial clinical trial. The I-SPY COVID Trial will evaluate the efficacy of cenicriviroc, a chemokine (CCR2 and CCR5) dual-receptor antagonist, Otezla , a PDE4 inhibitor, and Firazyr, a bradykinin B2 receptor antagonist in severely ill, hospitalized COVID-19 patients who require high-flow oxygen. The I-SPY COVID Trial utilizes Quantum Leap Healthcare collaborative's adaptive platform trial design, which is intended to increase trial efficiency by minimizing the number of participants and time required to evaluate potential treatments.

07:33 EDT Tyson Foods appoints Dean Banks to succeed Noel White as CEO - Tyson Foods announced that Dean Banks will succeed Noel White as CEO, while maintaining the role of President, effective October 3, 2020. White, who led Tyson through a period of unprecedented volatility and uncertainty when he assumed the CEO role in 2018, will remain with Tyson in a new role as Executive Vice Chairman of the board of directors. Banks' expanded role of CEO is part of the Board's deliberate, long-term succession planning. Since joining Tyson Foods as a director in 2017 and his appointment as President in 2019, Banks has worked closely with Tyson leadership to develop a greater understanding of the business and strategic vision for future growth.

07:31 EDT Bed Bath & Beyond to close stores on Thanksgiving Day in U.S., Canada - Bed Bath & Beyond announced plans to close its stores on Thanksgiving Day in the U.S. and Canada, including Bed Bath & Beyond, buybuy BABY, Christmas Tree Shops, Harmon Face Values and Cost Plus World Market. The company will provide a full range of shopping options leading up to each country's Thanksgiving Day, including newly introduced 2-hour Buy-Online-Pickup-In-Store and contactless Curbside Pickup services, to make the Holiday shopping experience as safe and easy as possible. Customers will also be able to find all the latest Holiday deals online throughout the Thanksgiving period, for delivery in-home or to their local store.

07:29 EDT Plug Power brings hydrogen fuel cells to Asda - Plug Power (PLUG) is providing UK-based supermarket Asda (WMT) with hydrogen fuel cell solutions to power the lift truck fleet within the retail giant's extensive supply chain network. Asda's partnership with Plug Power includes a purchase order agreement for Plug Power's full-service GenKey solution, beginning at the UK facility in Skelmersdale. The turnkey solution includes fuel cells, hydrogen fueling equipment, hydrogen and service. This new customer continues Plug Power's growth in Europe and represents the first deployment at scale of hydrogen fuel cell technology for material handling within the United Kingdom. The effort reduces Asda's reliance on traditional lead acid batteries for power in their material handling fleet and is part of a broader initiative designed to make the company's operations more environmentally-friendly.

07:25 EDT McKesson up 1.9% after reporting Q1 results, raising FY21 EPS guidance - Shares are up 1.9% in pre-market trading to $153 per share.

07:24 EDT Jacobs reports Q3 backlog of 23.7B up 5% y/y, up 4% on pro forma basis

07:23 EDT Pintec Technology appoints Victor Huike Li as director, CEO - Pintec Technology announced the appointment of Dr. Victor Huike Li as CEO and director of the Company, effective immediately. Wei Wei, who has been on a medical leave of absence since September 2019, has tendered his resignation as the Company's CEO for health reasons, and Mr. Jun Dong has resigned from his position as PINTEC's acting CEO as a result of Dr. Li's appointment. Both Mr. Wei and Mr. Dong will continue to serve on the board of directors of the Company following their resignations from the Company's management. In addition, Ms. Xiaomei Peng has resigned from the Board due to personal reasons. Li joined PINTEC in 2019 subsequent to the acquisition of InfraRisk. After joining the Company, Dr. Li first served as head of international business and then as executive vice president for the Company prior to his current roles.

07:20 EDT G1 Therapeutics, Simcere enter license agreement for trilaciclib - G1 Therapeutic announced an exclusive license agreement for the development and commercialization of trilaciclib across all indications in Greater China. Discovered and developed by G1, trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy. Under the terms of the agreement, G1 will receive an upfront payment of $14M and be eligible to receive up to $156M in development and commercial milestone payments. Simcere will also pay G1 tiered low double-digit royalties on annual net sales of trilaciclib in Greater China. Simcere will have exclusive development and commercialization rights for trilaciclib for all indications in Greater China, and will participate in global clinical trials of trilaciclib. G1 retains development and commercialization rights to trilaciclib in all territories outside of Greater China. The companies will be responsible for all development and commercialization costs in their respective territories.

07:18 EDT Macau reports July casino revenue down 94.5% to 1.34B patacas - Macau's gaming bureau reported July gross revenue from games of fortune in the region decreased 94.5% year-over-year to 1.344B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO).

07:18 EDT Zovio reports total enrollment of 34,395 students at June 30 - Total student enrollment at the company's academic institution was 34,395 students at June 30, compared with total student enrollment of 37,910 at June 30, 2019.

07:17 EDT McKesson reports Q1 U.S. Pharmaceutical and Specialty Solutions sales $45.1M - McKesson said in its Q1 earnings release, "U.S. Pharmaceutical and Specialty Solutions Segment Q1 revenues were $45.1 billion, up 2%, driven by market growth and higher volumes from retail national account customers, partially offset by branded to generic conversions and lower prescription volumes in the quarter. First-quarter Segment Operating Profit was $608 million and operating margin was 1.35%. Adjusted Segment Operating Profit was $589 million, down 2% from a year ago, driven by lower prescription volumes, partially offset by growth in the specialty provider business. Adjusted operating margin was 1.31%, down 5 basis points."

07:13 EDT McKesson reports Q1 U.S. Pharmaceutical and Specialty Solutions sales $45.1M - McKesson said in its Q2 earnings release, "U.S. Pharmaceutical and Specialty Solutions Segment Q1 revenues were $45.1 billion, up 2%, driven by market growth and higher volumes from retail national account customers, partially offset by branded to generic conversions and lower prescription volumes in the quarter. First-quarter Segment Operating Profit was $608 million and operating margin was 1.35%. Adjusted Segment Operating Profit was $589 million, down 2% from a year ago, driven by lower prescription volumes, partially offset by growth in the specialty provider business. Adjusted operating margin was 1.31%, down 5 basis points."

07:12 EDT Globant acquires cloud transformation services company, gA - Globant announced the acquisition of gA, "a leading digital and cloud transformation services company" with presence in the United States, Argentina, Brazil, Chile, Colombia, Mexico and Spain. Terms of the transaction were not disclosed.

07:11 EDT Senmiao Technology signs cooperation agreement with large auto dealer group - Senmiao Technology has signed a strategic cooperation agreement with Sichuan Hongyu Enterprise Management to facilitate the purchase of electric vehicles and cross-promote their brands, products and services for a term of three years, with a goal to further expand its automobile transaction and related services business. Based in Chengdu, Hongyu Auto is one of the largest auto dealer groups in southwest China. Hongyu Auto will promote Senmiao's Auto Business to EV manufacturers. Senmiao in turn plans to utilize the auto financing affiliates of the EV manufacturers with the goal of facilitating Senmiao's purchase of over 2,000 EVs at favorable costs for ride-hailing drivers and for other commercial use over a three-year period. Senmiao's EV procurement process will also be partially funded by the recently announced $7.0M capital contribution from Hongyi Industrial Group expected to be received by Senmiao's variable interest entity engaged in its Auto Business. Senmiao also intends to open additional retail stores or maintain its brand presence at Hongyu Auto's dealerships.

07:10 EDT Zovio, University of Arizona announce higher ed agreement - Zovio announced the signing of a definitive agreement to sell Ashford University to a newly formed non-profit entity that will bear the name of The University of Arizona Global Campus. Zovio will continue to provide its high-quality, innovative education technology services under a long-term Strategic Services Agreement. This partnership will offer nontraditional and underrepresented students access to flexible, affordable, high-quality higher education opportunities to achieve their academic and career goals. The new non-profit entity, The University of Arizona Global Campus, will acquire Ashford University and be fully-online, with its own accreditation, programs, and faculty in affiliation with the University of Arizona. Ashford University's faculty and approximately 35,000 students will continue coursework with no interruptions in degree programs.

07:09 EDT Cerecor receives Orphan Drug Designation for CERC-006 - Cerecor announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to CERC-006, a dual inhibitor of mTOR complexes 1 and 2 for the treatment of lymphatic malformations. Lymphatic malformations are a family of rare, congenital neoplastic diseases caused by mutations in certain genes that regulate cell growth in the lymphatic system. Children who suffer from this condition often have life-altering and in severe cases, life-threatening accumulation of fluid or growth affecting the head, neck and vital organs. LM appears at birth or in infancy and may persist throughout life. It is estimated that 30,000 to 60,000 Americans have this condition. Currently, there are no approved medicines for LM and affected children must often endure painful and potentially disfiguring surgery or sclerosis. As many as 20% of afflicted children die within 7 years.

07:08 EDT Noble Midstream maintains 2020 outlook, sees CapEx $60M-$80M - Noble Midstream 2020 organic capital expenditures expectations remain unchanged at $60 to $80 million with $20 to $40 million remaining in the second half of 2020. The Partnership has maintained its expected 2020 equity investment range of $240 to $260 million. The EPIC Y-Grade consortium is deferring the investment decision on the second greenfield fractionator until better line of sight to continued improvement in commodity prices. Second-half 2020 investment is planned for the expansion of the east dock at the EPIC Crude terminal to support larger vessels and funding the remaining EPIC Y-Grade construction payments. Noble Midstream expects minimal sponsor activity in the third-quarter 2020 and anticipates the resumption of Noble Energy well completions in the fourth quarter. The Partnership anticipates continued activity from third-party operators in the DJ Basin and now estimates more than 150 well connections this year at Black Diamond with 20 to 30 connections planned in the second half of 2020. With uncertainty around additional producer curtailments and the rate at which activity increases, Noble Midstream will not reinstate 2020 volume guidance at this time. Based on the existing curtailment and activity scenarios outlined in first-quarter 2020, Noble Midstream maintains its 2020 net Adjusted EBITDA expected range of $370 to $410 million and a Distributable Cash Flow1 range of $280 to $310 million for the year. Distribution coverage1 and leverage expectations remain unchanged as well.

07:05 EDT Bio-Techne, Kantaro Biosciences to launch COVID-19 serology test - Bio-Techne and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences, announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available for research use in early August. The COVID-SeroIndex test kit is an enzyme-linked immunosorbent assay, or ELISA, designed to measure the presence or absence of anti-COVID-19 antibodies in addition to measuring the titer of antibodies a person has produced. It utilizes not one, but two virus antigens: the full-length spike protein, and its receptor binding domain. The underlying technology was created by Mount Sinai's internationally recognized team of virologists and pathologists and has been tested on over 50,000 patient samples.

07:05 EDT Antares Pharma, Lunatus enter distribution agreement for XYOSTED - Antares Pharma announced they have entered into an exclusive distribution agreement with Lunatus Global Medical Supplies to distribute and promote the sale of XYOSTED in Saudi Arabia and the United Arab Emirates. Under the agreement, Antares will be responsible for the supply of fully packaged product to Lunatus and Lunatus will be responsible for submitting and obtaining regulatory approval for XYOSTED in Saudi Arabia and the UAE as well as marketing, promotion and distribution of XYOSTED in these two countries.

07:04 EDT FinTech Acquisition III, Paya announce definitive merger agreement - Paya, an integrated payments and commerce solution provider, and FinTech Acquisition Corp. III, a special purpose acquisition company, announced that they have entered into a definitive merger agreement. Upon closing of the transaction, the combined company will operate as Paya and will be listed on NASDAQ under the new symbol PAYA. The transaction reflects an implied enterprise value for the company of approximately $1.3B. The Paya management team, led by CEO Jeff Hack, will continue to execute the growth strategy of the company. Paya's existing majority equity holder GTCR, a private equity firm, will remain the company's largest stockholder. "We are excited to partner with FinTech III to accelerate our path to becoming a public company and greatly appreciate GTCR's continued investment and support," said Paya CEO Jeff Hack. "Paya has a long and proven history of creating differentiated value for software integration partners and their end customers. We have reached this milestone thanks to a terrific roster of software partners, as well as our talented and dedicated Paya colleagues. As a publicly listed company, we will continue to invest in the product innovation and support our software partners rely on to meet the needs of their clients, as well as have access to capital for additional strategic acquisitions," he continued. The cash component of the consideration will be funded by FinTech III's cash in trust as well as a private placement from various institutional investors, including Franklin Templeton and Wellington Management Company LLP, that will close concurrently with the merger. The balance of the consideration will consist of shares of common stock in the combined company. Existing Paya equity holders have the potential to receive an earnout of additional shares of common stock if certain stock price targets are met as set forth in the definitive merger agreement. Existing Paya equity holders, including GTCR and management, will remain the largest investors by rolling over significant equity into the combined company. Pursuant to the merger agreement, a newly formed entity, FinTech Acquisition Corp. III Parent Corp., will cause a merger subsidiary to merge with and into FinTech Acquisition Corp. III, resulting in FinTech Acquisition Corp. III Parent Corp. being the new parent company. The seller entities will then contribute and sell certain equity interests to FinTech Acquisition Corp. III Parent Corp. in exchange for the cash and equity consideration described above. Immediately following the closing, FinTech Acquisition Corp. III Parent Corp. will change its name to Paya Holdings Inc.

07:03 EDT AC Immune initiates IND-enabling studies for antibody targeting TDP-43 - AC Immune SA announced the initiation of investigational new drug-enabling studies for the Company's first-in-class therapeutic antibody targeting TDP-43. The anti-TDP-43 antibody is the first therapeutic candidate shown to mitigate TDP-43 neuropathology in vivo and the Company plans to develop the antibody for the treatment of NeuroOrphan indications. Advancing the anti-TDP-43 antibody towards clinical development is the latest in a series of important milestones already achieved this year in the Company's cutting-edge therapeutic and diagnostic programs targeting TDP-43 - which are amongst the most comprehensive in the field. TDP-43 pathology is strongly associated with cognitive decline and episodic memory loss in neurodegenerative diseases. Effectively slowing or stopping the spread of TDP-43 pathology throughout the brain could provide the first TDP-43 targeted therapeutic approach for treating conditions such as amyotrophic lateral sclerosis and frontotemporal lobar degeneration with TDP-43 pathology, where almost half of all FTLD cases exhibit TDP-43 pathology with significant market potential for AC Immune's TDP-43 antibody. Other indications include limbic-predominant age-related TDP-43 encephalopathy, and sub-populations of argyrophilic grain disease and Lewy Body Dementia. Additionally, pathological aggregation of TDP-43 has emerged as an important co-pathology in Alzheimer's disease linked to disease severity and occurring in ~50% of patients. Recognition that neurodegenerative diseases are driven by a complex interplay of pathologies highlights that successful treatments and cures will likely require combination therapy powered by precision medicine. This diversified approach is pioneered by AC Immune through parallel development of highly selective therapeutics and diagnostics for established targets like Tau and Abeta alongside newer targets such as TDP-43. TDP-43 is an RNA/DNA-binding protein that functions primarily in the nucleus as a regulator of gene transcription and RNA metabolism. TDP-43 pathology has been shown to start from a focal point in the brain and spread to other brain regions with disease progression. Antibody-mediated clearance of pathological TDP-43 therefore represents an attractive strategy for therapeutic intervention - potentially slowing the spread by blocking the ability of pathological TDP-43 to seed aggregation in neighboring healthy cells. The anti-TDP-43 antibody binds all forms of TDP-43 with high affinity and is the only antibody with reported in vivo activity. Proof-of-concept data presented at the 2020 AAT-AD/PD Conference demonstrated anti-TDP-43 antibody's ability to mitigate TDP-43 neuropathology in a mouse model of TDP-43 proteinopathies.

07:01 EDT Accenture awarded position on Air Force contract for Advanced Battle Management - Accenture subsidiary Accenture Federal Services has been awarded a position on a U.S. Air Force contract to build a modernized and interoperable Advanced Battle Management System. The contract leverages open systems design, modern software, and algorithm development in order to support the mission of Joint All Domain Command and Control. The five-year, indefinite-delivery/indefinite-quantity has a contract ceiling value of $950M and five option years.

06:58 EDT Zomedica CFO Shameze Rampertab resigns, Ann Cotter to act as interim CFO - Zomedica Pharmaceuticals announced that Shameze Rampertab has resigned as CFO and member of the Board of Directors, effective August 14. Ann Cotter, CPA, will act as interim CFO. Cotter has served as the Vice President of Finance for Zomedica from August of 2018, where she has taken a lead role in the internal accounting operations, as well as budgeting and forecasting responsibilities for the company. She has held various consulting, controllership and CFO roles for both private and publicly held companies and has public accounting experience in both audit and tax services.

06:57 EDT Sonoco acquires Can Packaging for approximately $49M - Sonoco announced it has acquired Can Packaging, a privately owned designer and manufacturer of sustainable paper packaging and related manufacturing equipment, based in Habsheim, France, for total consideration of approximately $49M. Founded by George Sireix in 1989, Can Packaging operates two paper can manufacturing facilities in France along with a research and development center where it designs and builds patented packaging machines and sealing equipment. Can Packaging is projected to produce sales of approximately $27M in 2020 and provides sustainable paperboard packaging to a number of large consumer food brands distributed across Europe. The business has approximately 60 associates.

06:51 EDT Exantas Capital announces acquisition of management contract by ACRES Capital - Exantas Capital said in a release, "Exantas Capital announced that ACRES Capital Corp. through its subsidiary, ACRES Capital, has acquired the Company's Management Agreement from an affiliate of C-III Capital Partners. In addition, the Company has entered into separate definitive agreements with Massachusetts Mutual Life Insurance Company and a fund managed by Oaktree Capital Management, L.P. for new capital commitments aggregating up to $375 million. The Company expects the new financing to provide ample liquidity to meet current financing requirements, and for new investments. As a result of the transaction, Exantas's new manager, ACRES, has assumed management responsibility effective immediately and will begin to implement the Company's business plan to preserve and grow book value and earnings. ACRES is a dedicated middle market commercial real estate lender led by a management team with extensive public company and mortgage REIT operating experience. ACRES has a robust asset management and origination platform along with a proven ability to source and maintain sponsor relationships, which will benefit Exantas as it restarts its origination efforts. The new financing agreements materially increase the liquidity profile of Exantas and are structured with flexible terms that create optionality, allowing the Company to take a proactive approach to asset management to drive value from the existing portfolio as well as opportunistically enhance its balance sheet. In connection with the transactions, ACRES and the Company entered into an Amended and Restated Management Agreement. Andrew Fentress and Mark Fogel, Co-Founders of ACRES, will serve as Chairman of the Board, and as President, CEO and Board member, of Exantas, respectively. Andrew Farkas and Jeffrey Cohen have resigned from the Board of Directors with immediate effect. ACRES has added 18 professionals from the former C-III team to its staff, including David Bryant, current CFO of Exantas, who will remain with the Company in his current role to maintain operational continuity."

06:47 EDT Virgin Galactic, Rolls-Royce sign MOU for design of engine propulsion technology - Virgin Galactic Holdings announced the first stage design scope for the build of its high speed aircraft design, and the signing of a non-binding Memorandum of Understanding with Rolls-Royce (RYCEY) to collaborate in designing and developing engine propulsion technology for high speed commercial aircraft. This follows the successful completion of its Mission Concept Review program milestone and authorization from the Federal Aviation Administration's Center for Emerging Concepts and Innovation to work with Virgin Galactic to outline a certification framework. This marks an exciting step forward in Virgin Galactic's development of a new generation of high speed aircraft, in partnership with industry and government leaders, with a focus on customer experience and environmental sustainability.

06:46 EDT Marathon Petroleum sees Q3 retail fuel sales 2B-2.2B gallons - Sees Q3 merchandise sales $1.7B-$1.8B.

06:37 EDT Clorox promotes Linda Rendle to CEO, Benno Dorer to continue as board chair - Clorox said in a release, "The board of Clorox announced that, effective Sept. 14, Linda Rendle, a 17-year veteran of the company, will be promoted to CEO and elected to the company's board. Benno Dorer will continue serving as the board's executive chair. Rendle is currently president of the company and prior to that was executive vice president - Cleaning, International, Strategy and Operations, among other leadership roles she has held at Clorox."

06:35 EDT Hermitage Offshore Services announces 10-day extension of forbearance agreement - Hermitage Offshore has agreed to a 10-day extension of its previously announced forbearance agreement to its $132.9M Term Loan Facility dated January 14 with DNB Bank ASA and Skandinaviska Enskilda Banken AB and DNB Bank ASA, as agent and security agent. While the extension of the Forbearance Agreement does not address the long-term liquidity and restructuring needs of the company, pursuant to the terms of the extended Forbearance Agreement, the Lenders have agreed to forbear from exercising any of their rights and remedies under the Term Loan Facility and any other finance agreements related to the Term Loan Facility in the event of a default by the company until August 10, 2020. The outbreak of the coronavirus coupled with the collapse in the price of crude oil has resulted in a significant and abrupt deterioration in the financial condition of the company. These events have given rise to substantial doubt about the company's ability to continue as a going concern. The company has engaged legal counsel to analyze restructuring alternatives and has been in ongoing discussions with the lenders in an effort to address these issues.

06:33 EDT DiamondPeak Holdings to list on Nasdaq through merger with DiamondPeak Holdings - Lordstown Motors and DiamondPeak Holdings (DPHC) announced they have entered into a definitive agreement for a business combination that would result in Lordstown becoming a publicly listed company. Upon closing of the transaction, the combined company will be named Lordstown Motors Corp. and is expected to remain listed on the NASDAQ and trade under the new ticker symbol, "RIDE." The business combination values Lordstown at an implied $1.6 billion pro forma equity value, at the $10.00 per share PIPE price and assuming minimal redemptions by DiamondPeak stockholders. The boards of directors of both DiamondPeak and Lordstown have unanimously approved the proposed transaction, which is expected to be completed in the fourth quarter of 2020, subject to, among other things, the approval by DiamondPeak's stockholders and satisfaction or waiver of the other conditions stated in the definitive documentation. The private placement of common stock includes commitments from institutional investors Fidelity Management & Research Company LLC, Wellington Management Company LLP, Federated Hermes Kaufmann Small Cap Fund, and funds and accounts managed by BlackRock, among others. The $75M investment from General Motors (GM) includes certain in kind contributions that have already been provided to Lordstown.

06:26 EDT Studio City announces private placements for $500M - Studio City has entered into subscription agreements with certain existing institutional shareholders and holders of its American depositary shares, including MCO Cotai Investments, a wholly-owned subsidiary of Melco Resorts & Entertainment, New Cotai, and Silver Point Capital, in relation to the series of private offers of its Class A ordinary shares. Upon completion of the Class A Private Placements, Studio City is expected to receive gross proceeds of approximately $500M.

06:24 EDT HSBC sees mid- to high-single digit percentage growth in RWAs in 2020 - HSBC said: "We expect mid-to-high single-digit RWA percentage growth in 2020, primarily from credit rating migration movements, which is expected to have an adverse impact on our CET1 ratio." It added: "Applying a range of weightings to our ECL sensitivity analysis could result in an ECL charge in the range of $8B-$13B for 2020."

06:10 EDT Ensign Group acquires post-acute care campus in Arizona - Ensign Group acquired the real estate and operations of a post-acute care retirement campus located in Tempe, AZ. The acquisition includes Tempe Post Acute, a 62-bed skilled nursing facility and Desert Marigold Senior Living of Tempe a senior living center with 72 assisted living beds and 90 independent living units. These acquisitions bring Ensign's portfolio to 226 healthcare operations. Ensign owns the real estate at 92 healthcare operations.

06:08 EDT Quotient sees FY21 sales of Alba $32M-$34M vs. $31.6M in FY20 - Sees FY21 Capital expenditures $5M-$10M. Average monthly cash use for operations in the range of $5M-$6M, excluding potential revenue related to COVID-19 antibody test. Alba by Quotient product sales in Q2 are expected to be within the range of $7.5M-$8.0M vs. $7.1M for 2Q20.

06:04 EDT Google to invest $450M to acquire 6.6% ownership in ADT - ADT (ADT) and Google (GOOG, GOOGL) announced they are entering into a long-term partnership to create the next generation of smart home security offerings. The partnership will combine Nest's award-winning hardware and services, powered by Google's machine learning technology, with ADT's installation, service and professional monitoring network to create a more helpful smart home and integrated experience for customers across the United States. The partnership will integrate Google's hardware and services and ADT's DIY and professionally installed smart home security solutions to innovate the residential and small business security industry. The future ADT + Google helpful home security solution is expected to advance smart home offerings and attract new consumers seeking premium technology, end-to-end smart home service and trusted security. ADT expects to offer certain Google devices to its customers beginning this year and to expand the integration in 2021. The complete ADT + Google helpful home security solution will utilize a secure platform for a seamless experience that prioritizes privacy and interoperability for greater customer peace of mind and choice. Google will make a $450 million investment in ADT in exchange for shares of a newly created Class B common stock having all of the rights and preferences of ADT's common stock except for the right to vote on the election, appointment or removal of directors. Upon the closing of Google's equity investment in ADT, Google will own 6.6% of ADT's outstanding aggregate common equity. Google's equity investment, which is subject to customary closing conditions, is expected to close in the third quarter of 2020. Proceeds will be used to fuel growth and reduce leverage over time. Each company will commit an additional $150M, subject to the achievement of certain milestones, to be used for co-marketing, product development, technology and employee training to advance the partnership. These investments are expected to accelerate ADT's capital efficient growth and drive broader consumer awareness and deeper product innovation for both companies in the fragmented yet rapidly expanding smart home market.

05:36 EDT NIO Inc. reports 3,533 vehicles in July - NIO Inc. provided its July 2020 delivery results. NIO Inc. said in a release, "NIO delivered 3,533 vehicles in July 2020, representing a robust 322.1% growth year-over-year. The deliveries consisted of 2,610 ES6s, the Company's 5-seater high-performance premium smart electric SUV, and 923 ES8s, the Company's 6-seater and 7-seater flagship premium smart electric SUV. As of July 31, 2020, cumulative deliveries of the ES8 and the ES6 reached 49,615 vehicles, of which 17,702 were delivered in 2020. On July 24, 2020, NIO announced the pre-subsidy price of the EC6, starting from RMB 368,000, and began taking production orders for the 5-seater premium smart electric coupe SUV. Its NEDC range of up to 615 kilometers with the 100 kWh battery pack, excellent driving experience, sporty and stylish design present a highly competitive model for a younger and broader user base. The EC6 deliveries will commence in September 2020."

05:33 EDT Aslan Pharmaceuticals appoints Kenneth Kobayashi, MD, as Chief Medical Officer - ASLAN Pharmaceuticals (ASLN) announced that Dr. Kenneth Kobayashi has been appointed Chief Medical Officer. Dr Kobayashi will be based in California and will be responsible for the global clinical development of ASLAN's pipeline, including the lead program, ASLAN004, an antibody that blocks the IL-13 receptor, which is being developed for atopic dermatitis. He most recently served as Senior Medical Director at Dermira, a subsidiary of Eli Lilly (LLY).

05:19 EDT Tailored Brands files voluntary Chapter 11 petitions - Tailored Brands said in a release, "Tailored Brands and certain of its subsidiaries announced that it has entered into a restructuring support agreement, or RSA, with more than 75% of its senior lenders. The RSA outlines agreed-upon terms for a pre-arranged financial restructuring plan that is expected to reduce the Company's funded debt by at least $630 million and provide increased financial flexibility to enable Tailored Brands to continue its focus on generating profitable growth and driving value for customers and stakeholders. To implement the terms of the RSA, the Company has filed voluntary Chapter 11 petitions in the United States Bankruptcy Court for the Southern District of Texas. Throughout the restructuring process, the Company expects that its four retail brands, Men's Wearhouse, Jos A. Bank, Moores Clothing for Men and K&G Fashion Superstore, will continue to provide customers with the selection, convenience, service and value that help people look and feel their best in the moments that matter, while continuing to prioritize the safety and well-being of employees and customers. Tailored Brands aims to move quickly through the process. The Company has received commitments for $500 million in debtor-in-possession, or DIP, financing from its existing revolving credit facility lenders. Following Court approval, this financing, combined with cash on hand (including approximately $90 million of restricted cash that the Consenting Term Loan Lenders (as defined below) have agreed to unrestrict and make available to the Company subject to certain terms and conditions), and cash flow generated by the Company's ongoing operations, is expected to be sufficient to meet the Company's operational and restructuring needs. The RSA further contemplates that the DIP financing will convert to a $400 million revolving credit facility from existing lenders upon the Company's emergence from Chapter 11. In addition to the financing relief described above, Tailored Brands has filed customary motions with the Court intended to allow the Company to operate in the ordinary course, including but not limited to: paying employees as usual and continuing pre-existing employee health and welfare benefits, honoring customer gift cards, rental reservations and custom clothing orders, and maintaining existing loyalty programs. These motions are typical in the Chapter 11 process and Tailored Brands anticipates that they will be heard and approved in the first few days of the cases. The decisions announced today build on the actions the Company announced on July 21, 2020 to reduce its corporate headcount, rationalize its store fleet, and reduce and realign its store organization and supply chain infrastructure and organization to best serve its go-forward store footprint and e-commerce business. Implementing the financial restructuring will allow Tailored Brands to continue its store optimization process to focus on and invest in the appropriate areas to position the business for the future."

05:15 EDT Pretium Resources reports fatality at Brucejack Mine - Pretium Resources reported in a press release, "a fatality resulting from an incident that occurred Friday, July 31st at the Brucejack Mine. The isolated incident occurred during maintenance at a support facility on surface. The injured employee was treated immediately by the site emergency response team and then transported to the hospital in Terrace, British Columbia where he passed away. Operations at Brucejack were suspended on Friday and have since resumed. The Company is fully cooperating with an investigation of the incident."